Law Of The Circulation Of Narcotic Drugs

Original Language Title: Gesetz über den Verkehr mit Betäubungsmitteln

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$20 per month, or Get a Day Pass for only USD$4.99.

Traffic law with narcotics (narcotics law-BtMG)

unofficial table of contents

btMG

date of issue: 28.07.1981

full quote:

" narcotics law in the version of the Notice of 1. March 1994 (BGBl. 358), as last amended by Article 2 of the Law of 20. May 2015 (BGBl. I p. 725) "

:Recaught by Bek. v. 1.3.1994 I 358;
Last modified by Art. 2 G v. 20.5.2015 I 725

See Notes

Footnote

(+ + + Text credits: 1.8.1981 + + +)
(+ + + measures) for more information on the standstill. due to EinigVtr no longer apply gem. Art. 109 No. 4
Buchst. c DBuchst. aa G v. 8.12.2010 I 1864 mWv 15.12.2010 + + +)
(+ + + Official note of the norm-provider on EC law:
compliance with the
EGRL 34/98 (CELEX Nr: 398L0034)
Notification of the
EGRL 34/98 (CELEX Nr: 31998L0034 cf. V v. 18.5.2015 I 723 + + +)

The law has been published as article 1 of the G v. 28.7.1981 I 681 approved by the Bundestag with the consent of the Bundesrat. It is on 1.1.1982 in accordance with. Art. 7 (1) (d). Gzur Neuordnung d. Anaesthesiological Law v. 28.7.1981 BGBl. 681, 1187 entered into force.
The provisions authorizing the adoption of legal regulations shall act in accordance with the provisions of this Regulation. Art. 7 (1) (d). G to reorder d. Anaesthesiological Law v. 28.7.1981 BGBl. 681, 1187 in force on the day after the announcement. The G was announced on 31 July 1981. unofficial table of contents

content overview

First section
Definitions
§ 1 Narcotics
§ 2Other terms
Second Section
Permission and permission procedure
§ 3Permission to traffic with narcotics
§ 4Exceptions to the Permission requirement
§ 5permission to sap
§ 6 Sachknowledge
§ 7Application
§ 8 Decision
§ 9Restrictions, restrictions, conditions, and conditions
§ 10Revocation and revocation
§ 10aPermission for the Operation of drug users
Third section
Duties in the Stun traffic
§ 11Imports, exports and transit
§ 12levy and purchase
§ 13prescription and delivery to prescribtion
§ 14Labeling and Advertising
§ 15 Backup Measures
§ 16Destruction
§ 17 Recordings
§ 18Messages
§ 18aVerbote
Fourth Section
Monitoring
§ 19Enforcement Authority
§ 20 Special authorization for the case of tension or defense
§ 21Participation of others Authorities
§ 22Monitoring measures
§ 23 sampling
§ 24Dulunding and co-action obligation
§ 24aViewing the attachment of usage hemp
§ 25Fees and Outlays
Fifth section
Authorities Rules
§ 26Bundeswehr, federal police, riot police and civil protection
§ 27 Messages and information
§ 28Annual Report to the United Nations
Sixth Section
Crimes and Administrative Offences
§ 29offences
§ 29aoffenses
§ 30offenses
§ 30aoffenses
§ 30boffenses
§ 30c Capital punishment
§ 31Punishment or Punishment of Punishment
§ 31aProsecutions from tracking
§ 32Administrative Offences
§ 33Extended decay and confiscation
§ 34 Guide Supervision
Seventh Section
Narcotics Dependent Offenders
§ 35Postal Enforcement
§ 36Invoice and Penal Enforcement
§ 37See of the pursuit
§ 38Young people and adolescents
Achter Section
Transitions and finishing rules
§ 39 Transitional control
§ 39aTransitional regulation on the occasion of the law on the amendment of the pharmaceutical law and other regulations
§ 40 and § 40a(non-applicable)
§ 41 (omitted)

First section
Definitions

Non-official table of contents

§ 1 narcotics

(1) narcotic agents within the meaning of this law are the substances and preparations listed in Annexes I to III.(2) The Federal Government is empowered to amend or supplement Annexes I to III after consultation of experts by means of a legal regulation with the consent of the Federal Council, if this is
1.
based on scientific knowledge about the mode of action of a substance, especially with regard to the Causing a dependency,
2.
because of the possibility of being able to produce narcotic drugs from a substance or using a substance, or
3.
on the safety or control of the transport of narcotic drugs or other substances or preparations on account of the extent of the abuse and because of the direct or indirect risk to health
. In the legal regulation referred to in the first sentence, individual substances or preparations may be exempted in whole or in part from the application of this law or by a regulation adopted pursuant to this Act, in so far as the security and the Control of the movement of narcotic drugs is guaranteed.(3) The Federal Ministry of Health shall be authorized, in urgent cases, to ensure safety or control of the movement of narcotics by means of a regulation without the consent of the Federal Council, substances and preparations which are not medicinal products, in to include Annexes I to III where this is necessary on account of the extent of the misuse and the direct or indirect risk to health. A Regulation adopted on the basis of this provision shall not enter into force after the end of a year.(4) The Federal Ministry of Health (Federal Ministry of Health) is authorized to amend Annexes I to III or the legal regulations issued pursuant to this Act without the consent of the Federal Council, in so far as this is due to the German Federal Ministry for Health (Federal Ministry of Health). Amendments to the Annexes to the Single Convention on Narcotic Drugs of 1961, as amended by the Notice of 4. February 1977 (BGBl. 111) and the Convention on Psychotropic Substances of 1971 (BGBl. 1477) (International Convention on Narcotic Drugs) is required in its version binding for the Federal Republic of Germany in each case. Unofficial table of contents

§ 2 Other terms

(1) For the purposes of this law,
1.
Fabric:
a)
chemical elements and chemical compounds, as well as their naturally occurring mixtures and solutions,
b)
Plants, algae, mushrooms and lichens as well as their parts and components in processed or unprocessed state,
c)
Animal body, also live animals, as well as body parts, ingredients and metabolic products of humans and animals in processed or unprocessed state,
d)
Microorganisms including viruses and their ingredients or metabolic products;
2.
Ready: regardless of their state of aggregation, a mixture of substances or the solution of one or more substances other than the naturally occurring mixtures and solutions;
3.
prepared preparation: a preparation, designated in Annexes I to III, which is wholly or partly based on the legislation of the general nature of the anaesthesiological legislation ,
4.
Production: the winning, making, preparing, working, processing, cleaning and converting.
(2) The import or export of a Any other placing in or out of the scope of this law is the same.

Second Section
Permission and permission procedure

Non-official Table of Contents

§ 3 Permission to Traffic with Narcotic Drugs

(1) A permission from the Federal Institute for Drugs and Medical devices require who
1.
grow, manufacture, trade with them, they, without to trade, import, export, issue, sell or otherwise place on the market, purchase or
2.
preparations (§ 2 para. 1 no. 3)
.(2) A permit for the narcotics referred to in Annex I may only be granted by the Federal Institute for Medicinal Products and Medical Devices to scientific or other purposes in the public interest. Non-tampering table of contents

§ 4 Exceptions to the requirement to obtain permission

(1) A permission in accordance with § 3 does not need to be granted to who
1.
as part of the operation of a public pharmacy or a hospital pharmacist (pharmacy)
a)
anaesthesia or preparations identified in Appendix II or III ,
b)
to acquire narcotic agent designated in Appendix II or III,
c)
in Appendix (
) '(a)' (a) '(a)' (a) '(a)' (a) '(a)' (a) '(a)' (a) '(a)' (
) ' (b)
(b)
Holder of a permit to buy these narcotics returns or to the successor in the operation of the pharmacy,
e)
referred to in Annex I, II or III Narcotics for examination, for forwarding to a site entitled to investigate narcotic drugs or for extermination, or
f)
in Appendix III in the form of ready-to-use medicinal products in transdermal or transmucosal form of administration to a pharmacy to cover the non-transferable anesthetic needs of an outpatient palliative patient, if the the receiving pharmacy did not supply the narcotics in stock
2.
in the context of the establishment of a veterinary skin pharmacist in Appendix III Anesthesia in the form of ready-to-use drugs
a)
for an animal treated by it, with
b)
b)
b)
acquires,
c)
for an animal treated by it or mixtures as referred to in point (a) for immobilization of a zoo, game and animal species treated by it, or
d)
returns to the holder of the licence to purchase these narcotic drugs or to the successor in the Operation of the veterinarian's home mortgage
3.
narcotic drugs referred to in Appendix III style="font-weight:normal; font-style:normal; text-decoration:none; ">
a)
due to medical, dentist, or veterinary prescription,
b)
to be used on an animal by a person who treats this animal and operates a veterinary skin pharmacist, or
c)
acquired by a doctor in accordance with § 13 (1a) sentence 1
,
4.
referred to in Appendix III Anaesthesia
a)
as a doctor, dentist or veterinarian in the context of the cross-border Services or
b)
has obtained medical, dental or veterinary prescription and it is a travel requirement
or
5.
gewerbingly
a)
involved in the transport of narcotic drugs between authorized participants in the carriage of narcotic drugs, or the storage and storage of narcotic drugs in connection with the (b)
the dispatch of narcotic drugs between authorized persons with such a transport or for an authorized participant in the transport of narcotic drugs; or
b)
Participants in the movement of narcotics by others concerned or mediated
6.
in Appendix I, II or III, narcotics designated as proband or Patient in the course of a clinical trial or in cases of hardship pursuant to Section 21 (2) (6) of the Medicinal Products Act, in conjunction with Article 83 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 December 2004. March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 327, 30.4.2004, p. 1).
(2) A permit in accordance with § 3 does not require federal and state authorities for the area of their official activities as well as the authorities responsible for the investigation of narcotics.(3) Those who do not require permission under paragraphs 1 and 2 of paragraph 1 and do not wish to participate in the transport of narcotics, have to notify the Federal Institute for Medicinal Products and Medical Devices beforehand. The display must contain:
1.
the name and addresses of the display and the pharmacy or the veterinary house pharmacist,
2.
the date of issue and the issuing authority of the apothecary permit or of the Approbation as a veterinarian and
3.
the date of the beginning of the participation in the narcotics traffic.
The Federal Institute for Medicinal Products and Medical Devices informs the competent top State authority immediately on the contents of the advertisements as far as they relate to veterinary skin pharmacies. Non-tampering table of contents

§ 5 refusal of permission

(1) The permission in accordance with § 3 is to fail if
1.
is not guaranteed to be in the factory and, if any other facilities are not in adjacent communities, in each of these premises a person is appointed who is responsible for the compliance with the legislation and the supervisory authorities (responsible); the Applicants may themselves take the place of a person responsible,
2.
the person in charge does not have the necessary expertise or the person responsible for it,
3.
Facts from which concerns have been raised against the reliability of the person responsible, the applicant, his or her own, and his/her own
4.
4.
4.
4.
style="font-weight:normal; font-style:normal; text-decoration:none;"> suitable rooms, facilities and fuses for the participation in the narcotics transport or the preparation of prepared preparations do not exist,
5.
the safety or control of the narcotics transport or the preparation of the preparations of other than the reasons given in points 1 to 4 are not
6.
The nature and purpose of the requested traffic, not with the purpose of this law, the necessary medical care for the population to ensure, in addition to that, the abuse of narcotic drugs or the abusive manufacture of preparations which have been taken abusive, as well as the removal or obtaining of a drug addiction, to the extent that it is possible to rule out the possibility of such abuse or
7.
if the submitted application documents are applied for, a defect is not remedied within the time limit set (§ 8 para. 2).
(2) The permission may be granted , if it is contrary to the implementation of the international drug agreements or decisions, orders or recommendations of intergovernmental bodies of narcotic control or to that due to acts adopted by the institutions of the The European Union is required. Non-official table of contents

§ 6 expertise

(1) The proof of the required expertise (§ 5 (1) no. 2) is provided
1.
in the case of the manufacturing of narcotics or excluded preparations, which are medicines, by providing evidence of the expertise referred to in Article 15 (1) of the German Medicines Act,
2.
in the case of the production of narcotic drugs which are not medicinal products, by means of Certificate of examination of a study of biology, chemistry, pharmacy, human or veterinary medicine completed after completing a scientific university degree, and confirmation of at least one year's practical activity in the Manufacture or testing of narcotic drugs,
3.
in the case of use for scientific purposes by the certificate of a post-completed scientific study University studies in biology, chemistry, pharmacy, human medicine or veterinary medicine, and
4.
in all other cases through the certificate of a completed vocational training as a merchant in wholesale and foreign trade in the fields of chemistry or pharma and through the confirmation of at least one year's practical activity in the field of narcotics.
(2) The Federal Institute for Medicinal products and medical devices may, on a case-by-case basis, derogate from the requirements referred to in paragraph 1 where the safety and control of the transport of narcotic drugs or the preparation of the preparations of the medicinal product concerned is ensured. . Non-official table of contents

§ 7 Application

The application for the grant of a permit pursuant to § 3 is to be made in duplicate at the Federal Institute for medicinal products and medical devices which shall send a copy of the competent supreme state authority. The application must be accompanied by the following information and documents:
1.
the names, first names or the company and the addresses of the applicant and of those responsible,
2.
for those responsible for the evidence of the necessary expertise and explanations as to whether or not , and on the basis of the circumstances in which they are able to comply with the obligations imposed on them,
3.
a description of the location of the premises by location (where applicable), street, house number, building and building part, as well as the building's construction,
4.
a description of the existing safeguards against the Collection of narcotic drugs by unauthorized persons,
5.
the type of narcotics traffic (§ 3 para. 1),
6.
the type and estimated annual amount of narcotics to be produced or required,
7.
in (a) a short description of the production process, specifying the type and quantity of the starting materials or preparations, the intermediate and final products, the production (section 2 (1) (4)) of narcotics or preparations excluded, even if the starting materials or preparations, intermediate or final products are not anesthetic; in the case of preparations not divided, the percentages by weight, in the case of preparations which have been divided, the quantities by weight of the form each divided
8.
in the case of use for scientific or other purposes in the public interest, an explanation of the persecuted For the purpose of making reference to relevant scientific literature.
Non-official table of contents

§ 8 Decision

(1) The Federal Institute for medicinal products and medical devices shall decide within three months of the date of receipt of the application for the grant of the authorisation. It shall immediately inform the competent supreme state authority of the decision.(2) If the Federal Institute for Medicinal Products and Medical Devices gives the applicant the opportunity to remedy any defects in the application, the time limit referred to in paragraph 1 shall be set up to remedy the deficiencies or until the expiry of the time limit set for the remedy of the deficiencies. Deadline is inhibited. The inhibition shall begin with the day on which the applicant is notified of the request to remedy the deficiencies.(3) The holder of the permit shall immediately inform the Federal Institute for Medicinal Products and Medical Devices of any change to the information referred to in § 7. In the event of an extension of the type of narcotic or narcotic movement, as well as changes in the person of the holder of the permit or the location of the premises, with the exception of a building, a new permit shall be granted. apply. In the other cases, permission is changed. The competent supreme state authority shall be informed immediately of the amendment of the permit. Non-official table of contents

§ 9 Restrictions, restrictions, conditions, and conditions

(1) The permission is for the security and control of the To restrict the use of stunning medium-sized products or preparations of the preparations to the extent necessary. In particular, it must regulate:
1.
the nature of the narcotics and the Narcotics traffic,
2.
the estimated annual quantity and the inventory of narcotics,
3.
the location of the workplaces, and
4.
the production step and the resulting output, intermediate and end products, even if they are not narcotics.
(2) The permission can be
1.
fixedterm, with conditions enacted or connected with constraints, or
2.
after they have been issued in respect of the second sentence of paragraph 1, or other restrictions or conditions,
where this is necessary in order to ensure the safety or control of the transport of narcotic drugs or the preparation of the preparations of those products; or the authorization of the implementation of the international instruments of addiction or of decisions, orders or recommendations of intergovernmental bodies in the control of narcotic drugs, or because of acts adopted by the institutions of the The European Union is required. Unofficial table of contents

§ 10 Revocation and revocation

(1) The permit can also be revoked if it is within a period of time two calendar years have not been used. The time limit may be extended if a legitimate interest is credibly made.(2) The competent supreme state authority shall be immediately informed of the withdrawal or revocation of the permit. unofficial table of contents

§ 10a Permission to use drug consumption rooms

(1) requires permission from the competent top-level authority, who wants to set up a facility in whose premises narcotics addicts are given an opportunity to consume, or are granted, narcotics which are not prescribed by medical practice (drug consumption room). Permission may be granted only if the State Government has laid down the conditions for granting it in accordance with the provisions of paragraph 2 of this Regulation.(2) The State Governments shall be empowered to regulate by means of a regulation the conditions for the granting of a permit referred to in paragraph 1. In particular, the rules must lay down the following minimum standards for the safety and control of the consumption of narcotic drugs in drug consumption rooms:
1.
Purpose factual equipment for use as a drug consumer room;
2.
Ensuring Immediate Medical Emergency Care;
3.
Medical Counseling and Assistance for the purpose of risk reduction in the consumption of narcotics carried along by addicts;
4.
Mediation of further and exit-oriented narcotics Offers of advice and therapy;
5.
Measures to prevent offenses under this law in drug consumption rooms, apart from the possession of narcotic drugs after Section 29 (1) sentence 1 no. 3 on own consumption in small quantities;
6.
required forms of cooperation with the public security and order competent authorities local authorities to prevent, as far as possible, criminal offences in the immediate vicinity of the drug-consuming premises;
7.
The exact definition of the county of the eligible persons Users of drug users, in particular with regard to their age, the type of narcotics carried along and the tolerated patterns of consumption; obvious first or occasional consumers are from the use of
8.
a documentation and evaluation of the work in the drug consumer spaces;
9.
The permanent presence of personally reliable personnel in sufficient number to meet the requirements set out in points 1 to 7. ,
10.
Designation of a knowledgeable person who is responsible for compliance with the requirements set out in points 1 to 9, the requirements of the authorisations authority and the requirements of the
(3) For the permission procedure, § 7 sentence 1 and 2 Nos. 1 to 4 and 8, § § 8, 9 para. 2 and § 10 Accordingly, the Federal Institute for Medicinal Products and Medical Devices shall be replaced by the competent supreme state authority, the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte).(4) A permit referred to in paragraph 1 shall not entivide the staff working in a drug consumption room to carry out a substance analysis of the narcotics carried on or to give active assistance in the direct consumption of the narcotic drugs carried on.

Third section
Obligations in narcotics traffic

Non-official Table of contents

§ 11 Import, export and transit

(1) Any person who wants to import or export narcotics on a case-by-case basis requires the necessary permission in accordance with § 3 of the Federal Institute for Medicinal Products and the Federal Institute for Medicinal Products and Medicine. Medical devices. Narcotics may be subject to the scope of this Act only under customs supervision without further than the stay-related stay and without the narcotic effect at any time during the period of Where it is actually available to the performing person or to a third person, it shall be carried out. Preparations which have been excluded may not be exported to countries which have prohibited the import.(2) The Federal Government is empowered to regulate the procedure for the granting of the authorisation by means of a regulation without the consent of the Federal Council, and to adopt rules on the import, export and transit in so far as it is intended for safety or security. Control of the movement of narcotic drugs, the implementation of international instruments of narcotics of narcotics, or of legislative acts of the institutions of the European Union. In particular,
1.
can import, export or transit to certain narcotic agents and quantities 2
2.
Exceptions to paragraph 1 for the travel and dispatch of samples in the Framework of international cooperation allowed,
3.
Regulations on the carrying out of narcotics by doctors, dentists and veterinarians within the framework of the
4.
Form, content, production, issue and retention of the official forms to be used
. Non-official table of contents

§ 12 levy and purchase

(1) Narcotic drugs may only be delivered to
1.
People or associations of persons who are in possession of a permit pursuant to § 3 for acquisition or a Pharmacies or veterinary house pharmacies,
2.
the authorities or bodies referred to in § 4 (2) or (26),
3. (2) In addition to the cases of § 4 (1) (1) (e), the donor shall immediately inform the Federal Institute for Medicinal Products and Medical Devices of any individual charge, indicating the acquirer and the type and quantity of the narcotic agent. report. The acquirer has to confirm receipt of the narcotics to the transferee.(3) Paragraphs 1 and 2 shall not apply to
1.
Disposal of narcotics referred to in Appendix III
a)
on the basis of medical, dental or veterinary prescription as part of the operation of a Pharmacy,
b)
in the context of the establishment of a veterinary skin pharmacist for an animal treated by the operator of this home pharmacy,
c)
by the doctor in accordance with § 13 paragraph 1a sentence 1,
2.
the export of narcotic drugs and
3.
The submission and purchase of narcotics between the authorities or bodies referred to in § 4 (2) or (26).
(4) The Federal Ministry of Education and Research Health is authorized to regulate the proceedings of the notification and the acknowledgement of receipt by means of a regulation without the consent of the Federal Council. In particular, it may regulate their form, content and storage as well as electronic transmission. Non-official table of contents

§ 13 prescribing and dispensing on prescription

(1) The narcotics listed in Appendix III may only be used by physicians, Dentists and veterinarians, and only prescribed or in the course of a medical, dental or veterinary treatment, including the medical treatment of a narcotic drug addiction, or another person to be treated for the treatment of a veterinary medicinal product. immediate consumption or, in accordance with paragraph 1a, first sentence, if their application is based on or in the human or animal body. The application shall not be justified, in particular, if the intended purpose can be achieved in other ways. The narcotics referred to in Annexes I and II may not be prescribed, administered or left to any other person for direct consumption or in accordance with the first sentence of paragraph 1a.(1a) In order to cover the non-suspensive agent needs of an outpatient palliative patient, the doctor may leave the necessary means of narcotics, designated in Annex III, in the form of ready-to-use medicinal products for this purpose only; as long as the patient's needs cannot be met in time by a prescription; the maximum amount of injunction shall not exceed the three-day requirement. The need for the patient cannot be covered by a prescription in time if the required anesthetic agent
1.
at a service-ready pharmacy within the same circle or circular city, or in neighboring counties or towns not in stock, or not in stock is available in time for delivery or
2.
although it is available in a pharmacy according to the number 1 or is available in time for delivery, by the patient or by the patient. patients cannot be procured in a timely manner because
a)
these persons are the Patients who need to be able to supply the anesthetic, or
b)
the patient, are not in a position to supply the narcotics or because of their limited capacity. because of the nature and extent of its disease, it is not itself able to do so and there are no people who provide the patient
The doctor must indicate that there is a situation in accordance with the first sentence of sentence 1, a pharmacy in accordance with the second sentence of the second sentence of the second subparagraph, whether the necessary narcotic agent is in stock there or until when it is ready for delivery. The doctor must keep at least the following records of the conditions laid down in sentences 1 and 2 and the question referred to in the third sentence, and keep these records for three years from the date of release of the anesthetic:
1.
the name of the patient as well as the location, date and time of the treatment,
2.
the name of the pharmacy and the contacted pharmacist or the person who is authorized to represent it,
3.
the name of the narcotics surveyed,
4.
the indication of the pharmacy, whether the anesthetic at the time of the request, or until when it is available for submission,
5.
the information on the facts from which the conditions are met; in accordance with sentences 1 and 2.
The pharmacist or the person entitled to his/her representative must be responsible for the question of a doctor treating in accordance with the first sentence, whether a certain narcotic agent is in stock or when it is available for delivery. at least the following records and shall keep them three years from the date of the request:
1.
the date and time of the request,
2.
the name of the doctor,
3.
the name of the narcotics surveyed,
4.
indicating to the doctor whether the Anesthesia is available at the time of the request or until when it is ready for delivery.
In the case of the transfer according to the first sentence, the doctor has the palliative patient or third party who is in the care of the ambulant to take care of the patient. to clarify the correct use of the narcotic narcotics and to issue a written instructions for use with information on the individual and daily doses.(2) The narcotics prescribed in paragraph 1 may only be delivered in the course of the operation of a pharmacy and upon presentation of the prescription. Diamorphine may only be delivered by the pharmaceutical operator and only by recognised bodies referred to in the second sentence of paragraph 3, second sentence, against presentation of the prescription. In the course of the operation of a veterinary medicine, only the narcotic agents listed in Annex III may be released and only for use in the case of an animal treated by the operator of the skin pharmacoe.(3) The Federal Government is authorized, by means of a legal regulation with the consent of the Federal Council, to write the narcotics referred to in Appendix III, their charge on the basis of a prescription and the recording of their whereabation and of the Stock of doctors, dentists, veterinarians, pharmacies, veterinary hospital pharmacy, hospitals, animal clinics, old and nursing homes, hospices, facilities of specialized outpatient palliative care, facilities of the Rescue services, facilities in which treatment with the substitution agent diamorphine takes place, and to the rules on commercial vessels to the extent necessary to ensure the safety or control of the transport of narcotic drugs. In particular,
1.
can be used to prescribe certain preparations, destinations or quantities
2.
The prescribing of substitution funds for drug addicts from the fulfilment of minimum requirements to the qualification of prescribers
2a.
the prescribying of Diamorphin only in institutions to which a permit has been granted, and
are subject to the definition of the minimum requirements of the medical chambers. has been granted by the competent State authority,
2b.
the minimum requirements for the equipment of the facilities in which the treatment with the substitution agent diamorphine, set,
3.
messages
a)
the prescribing physicians to the Federal Institute for Medicinal Products and Medical Devices about the prescribing of a substitution agent for a patient in anonymized Form,
b)
The medical chambers of the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) on doctors who meet the minimum requirements specified in point 2. and
messages
c)
of the Federal Institute of Medicinal Products and Medical Devices to the competent authorities Surveillance authorities and doctors prescribing the patients who have already prescribed a substitution agent to another doctor, in anonymized form,
d)
of the Federal Institute for Medicinal Products and Medical Devices to the competent surveillance authorities of the countries about the physicians who meet the minimum requirements according to point 2 ,
e)
the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) to the supreme state health authorities on the number of patients to whom a substitution agent, the number of doctors entitled to prescribe a substitution agent, the number of physicians who have prescribed a substitution agent, the prescribed substitution agents and the nature of the Prescriber
, as well as the type of anonymization, form and content of the messages and notices required,
4.
Form, content, production, edition, retention and Return of the official form to be used for the prescription, as well as the records of the whereabout and the stock, and
5.
Exceptions to § 4 1 (c) for the equipment of commercial vessels.
For the procedure for the granting of a licence pursuant to the second sentence of 2 (2a), § 7 sentence 2 (1) to (4), § 8 (1) sentence 1, (2) and (3) sentence 1 to 3, § 9 (2) and § 10 accordingly. The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte) is replaced by the Federal Institute for Drugs and Medical Devices, respectively. The recipients referred to in the second sentence of paragraph 3 shall not use the data transmitted for a purpose other than those referred to in sentence 1. The Federal Institute for Medicinal Products and Medical Devices is acting in the exercise of the tasks assigned to it by means of a decree in accordance with the second sentence of the second sentence, as the institution of the respective competent country, which is the subject of the federal government; details including Payment of expenses to the federal government shall be governed by agreement. Non-official table of contents

§ 14 Labelling and advertising

(1) In the field of narcotics, the narcotic agents are used in the List of listed short names. The marking has to be made in clearly legible writing, in German language and in a permanent way.(2) The marking must also contain
1.
in the case of raw, uncleaned and undivided Narcotics, the weight of the weight of the pure substance contained in the weight percentage and the weight of the narcotic agent being divided,
2.
on anesthetic containers and- in so far as it is used, the quantity by weight of substances and undivided preparations, in the case of substances and preparations not divided, the number of quantities in which the preparations are divided; this does not apply to storage containers in scientific laboratories; as well as for small containers and ampoules intended for delivery.
(3) Paragraphs 1 and 2 shall not apply to storage containers in pharmacies and veterinary home pharmacies.(4) Paragraphs 1 and 2 shall also apply mutagens to the name of narcotics, to catalogues, price lists, advertisements or similar printed products intended for the professional circles involved in the transport of narcotic drugs.(5) For narcotics referred to in Annex I, it shall not be allowed to advertise. Narcotic drugs referred to in Annexes II and III may be advertised only in professional circles in the industrial and commercial sectors and in persons and persons ' associations operating a pharmacy or a veterinary hospital pharmacy, for the installation of a veterinary medicinal product. III, also in the case of doctors, dentists and veterinarians. Non-official table of contents

§ 15 Save measures

Those who participate in the narcotics transport have the narcotics that are in their possession. shall be stored separately and shall be secured against unauthorised removal. The Federal Institute for Medicinal Products and Medical Devices may order precautionary measures in so far as it is necessary according to the nature or extent of the drug traffic, the degree of risk or the amount of the narcotic agents. Non-official table of contents

§ 16 Destruction

(1) The owner of narcotic drugs that are no longer marketable has the same at its cost in To destroy the presence of two witnesses in a way that excludes the only partial recovery of the narcotics and ensures the protection of man and the environment from harmful effects. The destruction is to be completed and to be kept for three years.(2) The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), in the cases of § 19 (1) sentence 3, the competent authority of the country, may ask the owner to send the narcotics at its costs to these authorities for the destruction. If an owner of the narcotics does not exist or is not to be identified, or the owner of his obligation to destroy or call for the submission of the narcotics pursuant to sentence 1 does not occur within a previously set Within three months, the authorities referred to in the first sentence shall take the measures necessary to destroy them. The owner or owner of the narcotics is obliged to give the narcotics the persons responsible for the destruction or to tolerate the removal.(3) (1) and (2), first and third sentences, shall apply accordingly if the owner does not wish to remove any more necessary narcotic drugs. Non-official table of contents

§ 17 Records

(1) The holder of a permit pursuant to § 3 is required to be separated for each establishment and each Deception means continuously keep the following records of each access and each departure:
1.
the date,
2.
the name or company and the address of the supplier or the recipient or the other origin or whereabout,
3.
the quantity received or lost and the resulting stock,
4.
in the case of the crop, in addition the area by location and size as well as the date of the sowing,
5.
in the Where production is concerned, in addition, the indication of the narcotics used or produced, the substances not subject to the law, or the prepared preparations by type and quantity, and
6.
in the case of the release of the preparations by their manufacturer, the name or the name of the company and the address of the recipient.
Records may be kept on a continuous basis after the date of the invoice, the copies of the original invoices in which the prepared preparations are marked.(2) The quantities to be entered in the records or invoices are
1.
for substances and not divided preparations by weight and
2.
in the case of divided preparations, the number of pieces.
(3) The records or copies of the invoice are three years, from the last record, or from the last invoice date, to be kept separately. Non-official table of contents

§ 18 notifications

(1) The holder of a permit under § 3 is obligated to the Federal Institute for Drugs and Drug Administration (Bundesinstitut für Arzneimittel und Bundesinstitut für Arzneimittel und to report medical devices separately for each plant and for each anesthetic, to report the quantity
1.
during cultivation, with the area by location and size,
2.
was produced, broken down by starting materials,
3.
used for the manufacture of other narcotics, broken down by these narcotics,
4.
for the manufacture of substances not covered by this law, broken down by these substances,
5.
used to produce ausgenommener preparations, broken down by these preparations,
6.
introduced, broken down by exporting country,
7.
, broken down by Importing countries,
8.
acquired,
9.
delivered,
10.
Destroyed,
11.
was used for purposes other than those specified in numbers 1 to 10, broken down by purpose and
12.
at the end of each calendar half-year as a stock.
(2) The messages in the messages the quantities to be added are
1.
for substances and undivided preparations, the amount by weight and
2.
for split preparations the number of pieces.
(3) The notifications pursuant to paragraph 1 (2) to (12) are the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) in each case up to 31. January and 31. July for the past calendar half-year and the notification referred to in paragraph 1 (1) to (31). May be sent in January for the previous calendar year.(4) For the notifications referred to in paragraph 1, the official forms issued by the Federal Institute for Medicinal Products and Medical Devices shall be used.

Fourth Section
Monitoring

unofficial table of contents

§ 19 Enforcement authority

(1) The narcotics traffic and the production of the Preparations are subject to supervision by the Federal Institute for Drugs and Medical Devices. This body shall also be responsible for producing, issuing and evaluating the official forms prescribed for the prescription of narcotic drugs. The movement of narcotics in doctors, dentists and veterinarians, pharmaceutical companies in the case of the dispensing of diamorphine and in pharmacies and, in the case of § 4 (1) (1) (f), between pharmacies, veterinary medicinal products, Hospitals and veterinary clinics are subject to surveillance by the competent authorities of the countries. They also monitor compliance with the minimum standards set out in § 10a (2); the persons responsible for monitoring are entitled to the powers provided for in § § 22 and 24.(2) The Federal Institute for Drugs and Medical Devices is at the same time the special administrative service in the sense of the international addictive surplus income.(3) The cultivation of farmed hemp within the meaning of point (d) of the derogation for cannabis (marijuana) in Annex I is subject to supervision by the Federal Institute for Agriculture and Food. The first subparagraph of Article 45 (4) and the Annex to Commission Implementing Regulation (EU) No 809/2014 of 17 May 2014. July 2014 laying down detailed rules for the implementation of Regulation (EU) No 1306/2013 of the European Parliament and of the Council as regards the integrated administration and control system, rural development measures and cross-compliance 1. 69), as amended, shall apply accordingly. In addition, the 2014 will apply accordingly. The Federal Agency for Agriculture and Food shall be entitled to the data transmitted to it by the competent national authorities in accordance with the rules of the Integrated Administration and Control System relating to the cultivation of hemp and to the results of the The use of the basic premium THC controls for the purpose of monitoring under this Act. Non-official table of contents

§ 20 Special authorization for a voltage or defense case

(1) The Federal Government is authorized to Legal regulation without the consent of the Federal Council of this Act or the legal regulations issued pursuant to this Act for defence purposes, in order to ensure the medical care of the population with narcotic drugs if: the safety and control of the transport of narcotic drugs or the preparation of preparations which have been removed shall be ensured. In particular,
1.
Tasks of the Federal Institute for Drugs and Medical Devices after this Law and regulations issued pursuant to this Act, transferred to the Federal Ministry,
2.
The transport of narcotics and the production of foreign goods. Preparations adapted to the special requirements referred to in sentence 1 and
3.
Reports on stocks at
a)
narcotics,
b)
Excluded Preparations and
c)
Starting materials required for the manufacture of narcotics or preparations, even if these are not anesthetic agents
In addition, the legal regulation may require persons entitled to dispose of the stocks referred to in the second sentence of paragraph 3 to be made available to certain persons or bodies.(2) The legal regulation referred to in paragraph 1 may only be applied in accordance with the provisions of Article 80a (1) of the Basic Law.(3) (omitted) Non-official table of contents

§ 21 Participation of other authorities

(1) The Federal Ministry of Finance and the Customs offices shall be involved in the control of the import, export and transit of narcotic drugs.(2) The Federal Ministry of Finance may, in agreement with the Federal Ministry of the Interior, the officials of the Federal Police, who are entrusted with tasks of border protection pursuant to § 2 of the Federal Police Act, and in agreement with the Bavarian State Minister of State of the Interior the officials of the Bavarian Border Police are entrusted with the performance of tasks which are the responsibility of the customs services referred to in paragraph 1. If the officials referred to in the first sentence are responsible for these tasks, Section 67 (2) of the Federal Police Act shall apply accordingly.(3) In the case of suspected violations of prohibitions and restrictions of this law, which result in the handling, the participating authorities shall immediately inform the Federal Institute for Drugs and Medical Devices. Non-official table of contents

§ 22 Monitoring measures

(1) The persons responsible for monitoring are authorized,
1.
Documents on the narcotics transport or manufacture or manufacture of the following The placing on the market of prepared preparations and the preparation of copies or copies thereof to the extent that they are relevant for the safety or control of the transport of narcotic drugs or preparations of the preparations of the preparations ,
2.
requires all necessary information from natural and legal persons and non-legal persons associations,
3.
plots, buildings, parts of buildings, facilities and means of transport in which the narcotics transport or the preparation of prepared preparations is carried out, to enter and visit, and the persons responsible have to be persuaded that the provisions relating to the transport of narcotics or the preparation of the preparations of the preparations are complied with. Whereas, in order to prevent urgent risks to public safety and public order, in particular where it is necessary to ensure that the control of the transport of narcotics or the preparation of preparations which have been carried out is to be fooled, these premises may also be used; are to be entered outside the operating and business hours as well as for residential purposes; in this respect, the fundamental right to inviolability of the apartment (Article 13 of the Basic Law) is restricted. As far as industrial manufacturing and wholesale operations are concerned, the visits are usually carried out every two years,
4.
provisional arrangements shall be made in so far as it is necessary for the prevention of urgent risks to the safety or control of the transport of narcotic drugs or the preparation of preparations which have been carried out. For the same purpose, they may also prohibit, in whole or in part, the further participation in the transport of narcotic drugs or the further production of preparations which have been taken out, and the stocks of narcotic drugs or the preparations of the preparations which have been taken out under official closure. The competent authority (Section 19 (1)) shall have a final decision on the provisional arrangements within one month of the adoption of the provisional arrangements.
(2) The competent authority may also take measures in accordance with paragraph 1 (1) and (2) by written means order. Non-official table of contents

§ 23 sampling

(1) To the extent that it is necessary to implement the rules relating to the transport of narcotics or to manufacture , the persons responsible for the monitoring shall be entitled to request or withdraw samples from their selection for the purpose of the investigation, in return for receipt of the certificate. Unless expressly waived, a part of the sample or, if the sample is not partially or without endangering the purpose of the examination, is not part of the same quality, a second piece of the same kind as the sample -withdrawn.(2) The samples to be returned shall be officially closed or sealed. They shall be accompanied by the date of the sampling and the date of the day after which the closure or sealing shall be deemed to have been lifted.(3) An appropriate compensation shall be provided for samples taken, unless expressly waived in this respect. Non-official table of contents

§ 24 Dulking and contributor obligation

(1) Each participant in the narcotics traffic or any manufacturer of the Preparations shall be obliged to tolerate the measures in accordance with § § 22 and 23 and to assist the persons responsible for monitoring in the performance of their duties, in particular to designate them at the request of the bodies in which the --------------------------------------------------------------------the- .(2) The information provided by the person concerned may refuse to answer such questions, the answers to which he or she himself or one of his relatives, referred to in § 383 (1) (1) to (3) of the Code of Civil Procedure, of the risk of criminal prosecution, or of a procedure under the Law on Administrative Offences. Non-official table of contents

§ 24a Display of the cultivation of usage hemp

The cultivation of usage hemp within the meaning of the letter d of the derogation on cannabis (marijuana) in Appendix I is up to 1. July of the cultivation year in triplicate of the Federal Institute for Agriculture and Food for the performance of their duties according to § 19 (3). The official form issued by the Federal Institute for Agriculture and Food is to be used for the display. The display must contain:
1.
the name, first name, and address of the farmer, in the case of legal entities. Persons the name of the enterprise of agriculture as well as the legal representative,
2.
the enterprise of agriculture by the competent Member/cadastre number assigned to the professional association,
3.
the sawn variety with the presence of the official labels, in so far as they are not within the framework of the regulations on the basic premium has been submitted to the competent State authority,
4.
the sowing area in hectares and Ar, indicating the area identification number; is not this number , the cadastral number or other information which has been recognized by the Federal Agency for Agriculture and Food, such as the Gemarkung, corridor and parcel, can be indicated.
The Federal Agency for Agriculture and Food shall immediately send a copy of the notification to the applicant without delay. It shall also send a copy of the notification to the competent police authorities and public prosecutors at their request, if this is necessary for the prosecution of criminal offences under this law. If the Federal Institute for Agriculture and Food provides evidence that the cultivation of farmed hemp does not comply with the conditions laid down in point (d) of the derogation for cannabis (marijuana) in Annex I, it shall inform the competent local authority of the competent authorities. Prosecutor's office. Non-official table of contents

§ 25 Fees and charges

(1) The Federal Institute for Drugs and Medical Devices collects for its individual pursuant to this Act and the legal regulations issued pursuant to this Act, fees and levies.(2) The Federal Ministry is authorized, by means of a regulation without the consent of the Federal Council, to determine the chargeable facts and to provide for fixed rates or framework rates.

Fifth Section
Authorities Rules

Non-official table of contents

§ 26 Bundeswehr, federal police, riot police and Civil protection

(1) This law, with the exception of the provisions concerning the permission pursuant to § 3, shall apply to facilities for the supply of narcotic drugs to the Bundeswehr and the Federal Police, as well as to the storage facility in Annex II or III. shall apply to the use of narcotic drugs for civil protection.(2) In the areas of the Federal Armed Forces and the Federal Police, the enforcement of this law and the supervision of the narcotics traffic are the responsibility of the respective competent authorities and experts of the Bundeswehr and the Federal Police. In the area of civil protection, the enforcement of this law is the responsibility of the federal and state authorities responsible for the stock of medical supplies.(3) The Federal Ministry of Defence may, in agreement with the Federal Ministry in individual cases, grant exceptions to this Act and to the legal regulations issued pursuant to this Act, in agreement with the Federal Ministry of Defence, to the extent that the -international drug-related incomes, which do not preclude and require compelling reasons of defence.(4) This Act shall apply, with the exception of the provisions relating to the authorization referred to in Article 3, to bodies serving the supply of narcotic drugs to the riot police of the countries.(5) (omitted) Non-official table of contents

§ 27 notifications and information

(1) The Federal Criminal Police Office reports to the Federal Institute for Drugs and Drug Administration (Bundesinstitut für Arzneimittel) Medical products annually up to 31. March for the previous calendar year, the seizures of narcotic agents according to nature and quantity which have become known to him and, where appropriate, the further use of the narcotic agents. In the case of recovery, the name or company name and address of the acquirer shall be indicated.(2) The authorities referred to in § 26 shall provide information to the Federal Institute for Medicinal Products and Medical Devices, on request, on the marketing of narcotic drugs in their areas, in so far as it is necessary to carry out the international SuchtstoffüberIncome is required.(3) In criminal proceedings which have the subject of criminal offences in accordance with this law,
1.
are to be transmitted to the Supervision and control of the movement of narcotic drugs in the persons and bodies referred to in Article 19 (1), third sentence, of the competent State authority, the final decision on the grounds that a penalty or a measure of the measure of the Improvement and security recognized or the accused has been acquitted of insolvency,
2.
for the performance of the tasks referred to in Article 19 (1) sentence 2 of the Federal Institute for Medicinal Products and Medical Devices in the case of the public action against doctors, dentists and veterinarians
a)
the indictment or an application written to their place,
b)
the application for a remission of Criminal command and
c)
the final decision on the basis of the decision; if an appeal has been or will be rejected by this decision, the decision shall be taken as a The person concerned shall also be notified of the contested decision
Theshall be initiated by the law enforcement authority or the law enforcement authority.(4) The decision concluding the procedure on grounds in other criminal cases may be forwarded to the competent State authority if there is a link between the offence and the movement of narcotic drugs and the knowledge of the decision is taken out of the point of view of the notified body is necessary for the monitoring of the movement of narcotic drugs; paragraph 3, first sentence, point 2 (c), second half-sentence shall apply accordingly. Non-official table of contents

§ 28 Annual Report to the United Nations

(1) The Federal Government shall annually reimburse up to the 30. The Secretary-General of the United Nations shall, in accordance with a form adopted by the United Nations Commission on Narcotic Drugs, provide an annual report on the implementation of international drug-addictive incomes in the past calendar year. The competent authorities of the countries will be involved in the preparation of the report and will submit their contributions to the 31. The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) in March for the past calendar year. In so far as the information required in the form cannot be determined, they are to be estimated.(2) The Federal Government is empowered to determine, by means of a regulation with the consent of the Federal Council, which persons and which bodies have to reimburse reports, namely statistical orders, other information and information, which shall be used for the purposes of: Implementation of the international addictive surplus income is required. In the Regulation, provisions may be made concerning the manner, form, timing and recipients of the notifications.

Sixth Section
Crime and Administrative Offences

unofficial table of contents

§ 29 offenses

(1) with a custodial sentence of up to five years or a fine will be punished for who
1.
Narcotics unallowed to grow, create, trade with them, do without trading, (§ 2 (1) (3)
2.
an excluded preparation (§ 2 (1) (3)).
3.
3.
3.
Stunning Means, without the permission of a written permission for the acquisition to be made. ,
4.
(dropped)
5.
contrary to § 11 para. 1 sentence 2 narcotics ,
6.
contrary to § 13 para. 1 narcotics
a)
verwrites,
b)
given or left to direct
6a.
contrary to § 13, paragraph 1a, sentences 1 and 2, leaving a narcotics referred to there,
7.
contrary to § 13 Paragraph 2
a)
Narcotic drugs in a pharmacy or veterinary house pharmacist,
b)
Diamorphin as a pharmaceutical entreprenator
,
8.
contrary to § 14 para. 5 for Advertise,
9.
means incorrect or incomplete information in order to prescribe, for itself or another animal, or for an animal, the prescription of a narcotic agent
10.
may give or grant to another person an opportunity to acquire or make an unauthorised purchase of narcotic drugs, such an opportunity Publicly or self-beneficial, or other than unauthorised use of narcotic drugs,
11.
without permission in accordance with § 10a of another one The opportunity for the unauthorised consumption of narcotic drugs is provided or granted, or who, outside a body according to § 10a, shares an opportunity for such consumption to be self-serving or publicly available,
12.
publicly, in a meeting or by spreading writings (§ 11 para. 3 of the Penal Code) to use narcotic drugs that are not permissible
13.
Money or other assets to another for an illegal act according to numbers 1, 5, 6, 7, 10, 11 or 12
14.
is contrary to a legal regulation pursuant to § 11 para. 2 sentence 2 no. 1 or § 13 para. 3 sentence 2 no. 1, 2a or 5, insofar as it is applicable to a certain event to this penal code.
The delivery of sterile disposable syringes to narcotic agents and the public information on it are not a creation and no public share of an opportunity for consumption as set out in the first sentence of 1 11.(2) In the cases referred to in the first sentence of paragraph 1 (1), (2), (5) or (6) (b), the experiment shall be punishable.(3) In particularly serious cases, the penalty is not less than one year. A particularly serious case is usually found when the offender
1.
in the cases referred to in paragraph 1, sentence 1 No. 1, 5, 6, 10, 11 or 13,
2.
by one of the actions referred to in the first sentence of paragraph 1, no. 1, 6 or 7, the health of several people
(4) If the offender is negligent in the cases referred to in the first sentence of the first sentence of paragraph 1, 2, 5, 6 (b), No 10 or 11, the penalty shall be for a period of up to one year or a fine.(5) The Court of First Instance may be punished by a punishment referred to in paragraphs 1, 2 and 4 if the offender only develops, manufactures, imports, carries out, carries out, acquires, acquires in any other way the narcotics in small quantities. provides or has.(6) The provisions of the first sentence of paragraph 1 are also applicable in so far as they relate to trading, giving or selling, where the act relates to substances or preparations which are not narcotic, but as such

Footnote

§ 29 para. 1 sentence 1 no. 1, 3, 5: According to the decision formula, it is compatible with the GG in accordance with the terms of the decision. BVerfGE v. 9.3.1994 I 1207-2 BvL 43/92 and a. - unofficial table of contents

§ 29a offences

(1) Imprisonment not under one year of imprisonment shall be punished for who
1.
as a person over 21 years of narcotics unauthorised to give or to a person under 18 years old Contrary to § 13 para. 1, or to direct consumption, or
2.
is not allowed to trade in small quantities with narcotic drugs, they are not allowed in (2) In less serious cases, the sentence is a custodial sentence of three months to five years.
(2) In minor cases the sentence is three months to five years. Non-official table of contents

§ 30 offenses

(1) Imprisonment not under two years is punished for who
1.
Narcotics unauthorised to grow, manufacture or trade with them (§ 29 para. 1 sentence 1 no. 1) and act as a member of a gang that has committed itself to continuing the commission of such acts,
2.
in the case of § 29a (1) (1) (1) (1) (1) of the Commercial Code
3.
emits narcotics, gives it to another, or leaves it for immediate consumption, thereby lightly causing death. or
4.
Inpermits of narcotics in a small amount unallowed.
(2) In minor cases, the penalty is imprisonment of three months up to five Years.

Footnote

§ 30 para. 1 no. 4: In accordance with the decision formula, it is compatible with the GG in accordance with the provisions of the German law. BVerfGE v. 9.3.1994-2 BvL 43/92 and a. - unofficial table of contents

§ 30a offences

(1) Imprisonment not less than five years is punishable by non-narcotic drugs in non-compliance Quantity unauthorised to grow, manufacture, trade with them, or execute them (§ 29 para. 1 sentence 1 no. 1) and act as a member of a gang which has joined in the continued commission of such acts.(2) Likewise, it shall be punished who
1.
as a person over 21 years of age shall designate a person under the age of 18 years, with Prohibitiy means trading unauthorised to drive, import, export, dispose, sell or otherwise place on the market or promote any of these acts without trade, or
2.
with narcotics in a small amount of unauthorised trade, or without trade, introduces, executes, or provides itself, and thereby a firearm or other In less serious cases, the sentence is punishable from six months to ten years.
(3) In less serious cases, the sentence is six months to ten years. Non-official table of contents

§ 30b offences

§ 129 of the Criminal Code shall also apply if an association, its purposes or its activities are the unauthorised distribution of narcotic drugs within the meaning of Section 6 (5) of the Penal Code is not, or not only, domesticated. Non-official table of contents

§ 30c asset penalty

(1) In the cases of § 29 (1) Nos. 1, 5, 6, 10, 11 and 13, § 43a of the Penal Code , This shall not apply in so far as the perpetrator sells, disposes, acquires, acquires himself or herself in any other way, without being able to trade, trade or trade with them.(2) In the cases of § § 29a, 30, 30a and 30b § 43a of the Criminal Code is to be applied. Non-official table of contents

§ 31 Penal mitigation or decrimination

The court may mitigate the sentence in accordance with Section 49 (1) of the Criminal Code or, if the offender did not have a custodial sentence of more than three years, depart from punishment if the offender
1.
by voluntary disclosure of his knowledge has contributed significantly to the fact that a criminal offence could be uncovered in accordance with § § 29 to 30a, which is related to his deed, or
2.
voluntarily its knowledge is disclosed in such a timely manner to a service that a criminal offence pursuant to section 29 (3), § 29a (1), § 30 (1), § 30a (1), the act with its deed in connection with the planning of which he/she knows or can be prevented from planning.
If the perpetrator was involved in the crime, his contribution to the Enlightenment according to the first sentence of 1 (1) must extend beyond his own contribution to the crime. § 46b (2) and (3) of the Penal Code shall apply accordingly. A non-official table of contents

§ 31a Prosecution of the persecution

(1) If the proceedings are subject to a breach of § 29 para. 1, 2 or 4, the Prosecution of the prosecution, if the perpetrator's guilt is to be regarded as low, there is no public interest in prosecution and the offender is merely building the narcotics for self-consumption in small quantities, manufactures, imports, carries out, acquires, acquires, or possesses in any other way. Apart from the persecution, if the perpetrator in a drug consumption room has a small quantity of narcotic drugs only for self-consumption, which can be tolerated in accordance with § 10a, without at the same time a written permission for the person to be used for the purpose of the drug use is not permitted. To be acquired.(2) If the action has already been filed, the court may, in any circumstances of the proceedings, set the procedure under the conditions set out in paragraph 1, with the consent of the Public Prosecutor's Office and the accused person. The consent of the accused is not required if the main hearing cannot be carried out on the grounds stated in § 205 of the Code of Criminal Procedure or in the cases of § 231 (2) of the Code of Criminal Procedure and § § 232 and 233 of the Criminal procedure is carried out in his absence. The decision shall be taken by decision. The decision shall not be countervailable. Non-official table of contents

§ 32 Administrative Offences

(1) Contrary to the law, who intentionally or negligently
1.
contrary to § 4 paragraph 3 sentence 1, not showing participation in the narcotics traffic,
2.
in an application according to § 7, also in conjunction with § 10a para. 3 or § 13 paragraph 3 sentence 3, makes incorrect information or adds incorrect documents,
3.
contrary to § 8 para. 3 sentence 1, also in conjunction with § 10a para. 3, a change is not correct, not complete or not immediately communicated,
4.
a workable edition according to § 9 para. 2, also in conjunction with § 10a para. 3,
5.
contrary to § 11 para. 1 sentence 1, narcotics without approval,
6.
one Pursuant to § 11 paragraph 2 sentence 2 no. 2 to 4, § 12 para. 4, § 13 para. 3 sentence 2 Nos. 2, 3 or 4, § 20 para. 1 or § 28 para. 2, insofar as it refers to this fine for a certain amount of facts,
7.
contrary to § 12 para. 1 narcotics or contrary to § 12 para. 2 the delivery or acquisition is not correct, not complete or not reported immediately or the reception is not confirmed,
7a.
contrary to § 13 (1a) sentence 3, not correct or not in good time at a pharmacy,
7b.
contrary to § 13, paragraph 1a, sentence 4 or 5, a record does not result, not correct or not complete, or a record not or not at least three years
8.
contrary to § 14, para. 1 to 4, narcotics not marked in accordance with the rules,
9.
an enforceable arrangement according to § 15 sentence 2 is contrary,
10.
contrary to § 16 para. 1 narcotics is not destroyed in accordance with the rules, does not produce a copy, or does not retain it or, contrary to § 16 (2) sentence 1, does not send a narcotic agent for destruction, also in connection with Section 16 (3),
11.
contrary to § 17 para. 1 or 2 records, not correct or not complete, or contrary to § 17 para. 3, records or invoice transcripts are not
12.
contrary to § 18 para. 1 to 3 reports, not correct, not fully or not reimbursed in time,
13.
contrary to § 24 para. 1 of a duty of duty or joint action,
14.
contrary to § 24a the Cultivation of usage hemp not, not correct, not fully or not displayed in time or
15.
A mail item placed in a mail item, even though this dispatch is prohibited by the Universal Postal Agreement or by an agreement of the Universal Postal Association; the secrecy referred to in Article 10 (1) of the Basic Law shall be restricted in so far as to the pursuit and prosecution of the administrative offence.
(2) Unlawfulness can be punished with a fine of up to twenty-five thousand euros.(3) The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte) is the Federal Institute for Drugs and Medical Devices Agriculture and nutrition. Non-official table of contents

§ 33 Extended decay and confiscation

(1) § 73d of the Penal Code is applicable
1.
in the cases of § 29 (1) sentence 1, no. 1, 5, 6, 10, 11 and 13, provided that the offender acts as commercial, and
2.
in the cases of § § 29a, 30 and 30a.
(2) Items to which a criminal offence relates in accordance with § § 29 to 30a or an administrative offence pursuant to § 32, can be recovered. Section 74a of the Criminal Code and Section 23 of the Law on Administrative Offences shall apply. Non-official table of contents

§ 34 Management supervision

In the cases of § 29 (3), § § 29a, 30 and 30a, the court may order management supervision (§ § § 29a, 30 and 30a). Article 68 (1) of the Penal Code).

Seventh Section
Narcotic Agents Dependent Offenders

unofficial table of contents

§ 35 Withdrawal of enforcement order

(1) If someone has been sentenced to a prison sentence of no more than two years for a criminal offence, and if it is clear from the reasons for the judgment, or if it is otherwise established that he has committed the act on the basis of a dependence on narcotics, the executing authority may, with the consent of the court of the first legal proceedings, execute the sentence, one Return the penal code or the rule of accommodation in an equestrian establishment for a maximum of two years if the convicted person is in a treatment serving for his or her rehabilitation, or if he or she is in a position to be in a shall be subject to such conditions and shall be guaranteed at the beginning. The treatment also applies to the stay in a state-approved facility, which serves to correct the dependency or to counteract a reliance.(2) In the event of a refusal of consent by the court of the first legal proceedings, the enforcement authority shall submit the appeal in accordance with the second section of the third book of the Code of Criminal Procedure. The convicted person may contest the denial of this consent only together with the rejection of the deferment by the executing authority in accordance with § § 23 to 30 of the Introductory Act to the Law Constitutional Law. In this case, the Oberlandesgericht also decides on the refusal of consent; it can give the consent itself.(3) Paragraph 1 shall apply by analogy if
1.
is a total custodial sentence of not more than two years or
2.
has been recognized for a term of imprisonment or a total custodial sentence of more than two years, and a remainder to be executed a custodial sentence or the total custodial sentence not exceeding two years
and, moreover, the conditions set out in paragraph 1 above are satisfied for the majority of the offences which have been given for their meaning.(4) The convicted person shall be obliged to provide proof of the admission and continuation of the treatment at the time of the enforcement of the enforcement authority; the persons or entities treating the person shall be obliged to provide proof of the Enforcement authority discontinuation of treatment with.(5) The executing authority shall revoke the deferral of enforcement if the treatment is not started or is not continued and is not to be expected that the convicted person shall immediately begin or resume treatment of the same kind, or if the convicted person does not provide the proof referred to in paragraph 4. The revocation may be waited if the convicted person subsequently proves that he is in treatment. A revocation pursuant to the first sentence shall not preclude the revocation of enforcement.(6) The revocation of enforcement shall also be revoked if
1.
in the case of subsequent formation of a The total penalty shall not also be returned to enforcement in accordance with paragraph 1 in conjunction with paragraph 3, or
2.
another person recognized against the convicted person (
)
the executing authority has withdrawn the revocation, it shall have the power to execute the custodial sentence or the lodging of the custodial sentence or the sentence of the sentence. to issue an arrest warrant in an equalising institution. The decision of the court of the first legal proceedings may be brought against the revocation. The continuation of enforcement shall not be inhibited by the appeal of the General Court. Section 462 of the Code of Criminal Procedure shall apply accordingly. Non-official table of contents

§ 36 Invoice and sentence on probation

(1) Enforcement has been suspended and has the If convicted persons are treated in a state-approved institution, the time of his stay in that institution, which has been proven by the convicted person, shall be credited to the penalty until two-thirds of the sentence is dealt with as a result of the offsetting. . The court of law shall at the same time take the decision on the validity of the invoice with the consent of Section 35 (1). If two-thirds of the penalty is settled by the offsetting or if a treatment is no longer necessary in the institution at an earlier date, the court shall suspend the execution of the sentence of the sentence on probation as soon as this is carried out under the conditions laid down in To take account of the safety interest of the general public.(2) Where enforcement has been completed and the convicted person has been subject to treatment other than the treatment referred to in paragraph 1, the court shall suspend the execution of the custodial sentence or the sentence of imprisonment of the person concerned. Probation as soon as this can be held responsible for the safety interest of the general public.(3) If, in fact, the convicted has undergone a treatment of his dependence, the court may, if the conditions laid down in the first sentence of paragraph 1 do not exist, order that the time of the treatment shall, in whole or in part, apply to the sentence , if this is indicated in the light of the requirements placed on the convicted person.(4) Articles 56a to 56g and 57 (5) sentence 2 of the Penal Code shall apply accordingly.(5) The decisions referred to in paragraphs 1 to 3 shall be taken by the court of the first legal proceedings without oral proceedings by decision. The executing authority, the convicted person and the persons or entities treating them shall be heard. An immediate complaint is possible against the decisions. In the case of the decisions referred to in the third sentence of paragraph 1 and in accordance with paragraph 2, Section 454 (4) of the Code of Criminal Procedure shall apply accordingly; the instruction on the suspension of the criminal proceedings shall be issued by the court. Non-official table of contents

§ 37 Departure from the collection of the public lawsuit

(1) A suspect is suspected of being a criminal offense of a drug addiction, and if no higher penalty than a custodial sentence of up to two years is to be expected, the Public Prosecutor's Office may, with the consent of the court responsible for the opening of the main proceedings, Provisional application of the public action if the accused proves that he is subject to his reliance on the treatment referred to in § 35 (1), and that his resocialisation is to be expected. The Public Prosecutor's Office shall determine the dates on which the accused has to prove the continued duration of the treatment. The procedure will continue if
1.
does not complete the treatment until it is completed.
2.
The accused does not lead the proof required by sentence 2,
3.
the accused commits an offence and thereby shows that the expectation that was based on the collection of the public lawsuit did not meet, or
4.
on the basis of new facts or evidence, a term of imprisonment of more than two years is to be expected.
In the cases of sentence 3, no. 1, 2, the the continuation of the procedure shall be waited if the accused subsequently proves that he is continuing to be in treatment. The action can no longer be pursued if the procedure is not continued within two years.(2) If the action has already been filed, the court may, with the consent of the Public Prosecutor's Office, provisionally set the proceedings before the end of the main hearing in which the actual findings can be examined at the latest. The decision shall be taken by means of an indisputable decision. The provisions of the second sentence of paragraph 1 shall apply mutatily. It is also indisputable that the procedure is not continued (paragraph 1). 1 sentence 5). (3) The provisions of § 172 (2) sentence 3, § 396 (3) and § 467 (5) of the Code of Criminal Procedure are applicable to § 153a of the Code of Criminal Procedure accordingly. Non-official table of contents

§ 38 Young people and adolescents

(1) In the case of sentencing to juvenile punishment, § § 35 and 36 shall apply mutatically. In addition to the commitment of the young person in accordance with § 35 (1) sentence 1, the consent of the legal guardian and the legal representative is also required. In the case of § 35 para. 6 sentence 2, § 83 para. 2 no. 1, para. 3 sentence 2 of the juvenile justice act shall apply mutationally. By way of derogation from Section 36 (4), § § 22 to 26a of the Juvenile Justice Act shall apply accordingly. In addition to Section 454 (4) of the Code of Criminal Procedure, § § 36 (1) sentence 3 and section 2 of the Code of Criminal Procedure are to be applied in addition to § § 58, 59 (2) to (4) and § 60 of the Juvenile Justice Act.(2) § 37 shall also apply to young people and adolescents.

Achter section
Transiting and closing rules

A non-official table of contents

§ 39 Transitional Regulation

institutions in whose premises the consumption of narcotic drugs that are not prescribed by a doctor before the 1. However, in the absence of a permit from the competent authority of the competent authority of the State of the State, only if no later than 24 months after the entry into force of the Third BtMG Amendment Act of 28 January 1999, the competent supreme state authority may not be allowed to March 2000 (BGBl. 302), a legal regulation pursuant to Section 10a (2) and a request for permission pursuant to Section 10a (1) of this Regulation shall be made. Pending the indisputable decision on an application, these institutions may only continue to operate, in so far as the requirements of Section 10a (2) or of a decree law adopted pursuant to this provision are fulfilled. Section 29 (1), first sentence, No. 10 and 11 shall also apply to bodies referred to in the first sentence. Non-official table of contents

§ 39a Transitional regulation on the occasion of the law on the amendment of pharmaceutical and other regulations

For a Person who does not have the expertise in accordance with Section 5 (1) (2), but on the 22. According to Article 141 (3) of the German Medicines Act (Medicines Act), the proof of the necessary expertise in accordance with Section 6 (1) (1) shall be deemed to have been fulfilled. Non-official table of contents

§ § 40 and 40a (non-conflicting)

unofficial table of contents

§ 41

(omitted) unofficial table of contents

asset I (to § 1 (1)
(non-marketable narcotics)

(Fundstelle: BGBl. I 2001, 1180-1186;
of the individual amendments, cf. Footnote)

1contains the International Nonproprietary Names (INN) of the World Health Organisation. In the name of a substance, the INN takes precedence over all other designations.
Column 2contains other non-protected Names of substances (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They are therefore to be used in conjunction with the designation in column 3.
Column 3contains the chemical name of matter after the nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no label is listed in column 1 or column 2, then the column 3 is to be used.
 
INN Other unprotected or trivialnames chemical names (IUPAC)
Acetorphin- {4, 5α-epoxy-7α-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethenomorphinan-3-yl} acetate
-acetyldihydrocodeine (4, 5α-epoxy-3-methoxy-17-methylmorphinan-6α-yl) acetate
acetylmethadol- (6-dimethylamino-4,4-diphenyl-heptan-3-yl) acetate
-Acetyl-α-methylfentanyl N-phenyl-N-[1-(1-phenyl-propane-2-yl)-4-piperidyl] acetamide
-- 4-Allyloxy-3,5-dimethoxy-phenethylazan
Allylprodin- (3-Allyl-1-methyl-4-phenyl-4-piperidyl) propionate
Alphacetylmethadol- [(3R, 6R) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
Alphameprodin- [(3RS, 4SR) -3-ethyl-1-methyl-4-phenyl-4-piperidyl] propionate
Alphamethadol- (3R, 6R) -6-dimethylamino-4,4-diphenylheptan-3-ol
Alphaprodin- [(3RS, 4SR) -1,3-dimethyl-4-phenyl-4-piperidyl] propionate
-5-(2-Aminopropyl) indole
(5-IT)
1-(1H-Indol-5-yl) propane-2-amine
Anileridin- Ethyl [ 1-(4-aminophenethyl)-4-phenyl-piperidin-4-carboxylate)
-BDB 1-(1,3-Benzodioxol-5-yl) butan-2-ylazane
benzethidine- Ethyl {1-[2-benzyloxy) ethyl]-4-phenyl-piperidin-4-carboxylate}
BenzfetamineBenzphetamine (benzyl) (methyl) (1-phenylpropan-2-yl) azan
-- 1-(1,3-Benzodioxol-5-yl) -2-(pyrrolidin-1-yl) propan-1-one
-benzylfentanyl N-(1-benzyl-4-piperidyl)-N-phenyl-propanamide
-benzylmorphin 3-Benzyloxy-4, 5α-epoxy-17-methylmorphin-7-en-6α-ol
Betacetylmethadol- [(3S, 6R) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
Betameprodin- [(3RS, 4RS) -3-ethyl-1-methyl-4-phenyl-4-piperidyl] propionate
Betamethadol- (3S, 6R) -6-dimethylamino-4,4-diphenylheptan-3-ol
Betaprodin- [(3RS, 4RS) -1,3-dimethyl-4-phenyl-4-piperidyl] propionate
Bezitramid- 4-[4-(2-Oxo-3-propionyl-2,3-dihydrobenzimidazol-1-yl) piperidino] -2,2,-diphenyl-butane nitrile
-25B-NBOMe
(2C-B-NBOMe)
2-(4-bromo-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
Brolamfetamine Dimethoxybromamfetamine (DOB)(RS)-1-(4-bromo-2,5-dimethoxy-phenyl) propane-2-ylazan
- Bromdimethoxyphenethylamine (BDMPEA)4-bromo-2,5-dimethoxyphenethyl-azan
- Cannabis
(marijuana, plants and plant parts of plants belonging to the genus cannabis)
-
-except
a)the seeds of which, unless they are not allowed to Cultivation is determined,
b)if they come from the cultivation in countries of the European Union with certified seed of varieties on the 15. March of the crop year in the Commission's Article 9 of the Delegates Regulation (EU) No 639/2014 of 11 June 2014. March 2014, supplementing Regulation (EU) No 1307/2013 of the European Parliament and of the Council laying down rules for direct payments to farmers under support schemes of the common agricultural policy and on the Amendment to Annex X to that Regulation (OJ L 327, 28.10.2000 1), the common catalogue of varieties of agricultural plant species referred to in the current version is listed, or its tetrahydrocannabinol content does not exceed 0.2 per cent and the traffic with them is not exceeded. (except for the cultivation) exclusively for commercial or scientific purposes, which exclude abuse for noise purposes,
c) if it is planted as a protective strip during beet breeding and destroyed before flowering,
d)if it is used by companies of agriculture, which satisfy the conditions laid down in Article 1 (4) of the Law on the Pensions of Farmers, with the exception of forestry, garden and wine-growing, fish farming, pond farming, the beekeeping, inland fishing and migrant shepherd, or the granting of aid under Regulation (EU) No 1307/2013 of the European Parliament and of the Council of 17 June 2013 on the granting of aid to the European Union for the period of 1 January 2013. December 2013 with rules on direct payments to farmers under support schemes of the common agricultural policy and repealing Council Regulation (EC) No 637/2008 and Regulation (EC) No 73/2009 Council Regulation (EC) No 608), as amended, and the cultivation of varieties exclusively from certified seed of varieties on the 15th of May, p. March of the crop year included in the common catalogue of varieties for agricultural plant species referred to in Article 9 of the Delegated Regulation (EU) No 639/2014 (usage hemp) or
e)to the purposes specified in Annexes II and III-
- Cannabis resin
(Hashish, the secreted resin of the plant belonging to the genus Cannabis)
-
Carfentanil-methyl [1-phenethyl-4-(N-phenyl-propanamido) piperidine-4-carboxylate]
Cathinon-(S) -2-amino-1-phenylpropan-1-on
-2C-C 2-(4-chloro-2,5-dimethoxyphenyl) ethanamine
-2C-D
(2C-M)
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine
-2C-E 2-(4-Ethyl-2,5-dimethoxyphenyl) ethanamine
-2C-l 4-lod-2,5-dimethoxyphenethyl-azan
-6-Cl-MDMA [1-(6-chloro-1,3-benzodioxol-5-yl) propan-2-yl] (methyl) azan
Clonitazen- {2-[2-(4-chlorobenzyl) -5-nitrobenzimidazol-1-yl] ethyl} diethylazane
-25C-NBOMe
(2C-C-NBOMe)
2-(4-chloro-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
-Codeine-N-oxide 4, 5α-epoxy-3-methoxy-17-methylmorphin-7-en-6α-ol-17-oxide
Codoxim- (4, 5α-Epoxy-3-methoxy-17-methylmorphinan-6-ylidene-aminooxy) acetic acid
-2C-P 2-(2,5-Dimethoxy-4-propylphenyl) ethanamine
-2C-T-2 4-Ethylsulfanyl-2,5-dimethoxy-phenetylazan
-2C-T-7 2,5-Dimethoxy-4-(propylsulfanyl) phenethylazane
Desomorphinedihydrodesoxymorphine 4, 5α-Epoxy-17-methyl-morphinan-3-ol
Diampromid- N-{2-[(methyl) (phenetyl) amino] propyl} -N-phenylpropanamide
-Diethoxybromamfetamine 1-(4-bromo-2,5-diethoxyphenyl) propane-2-ylazane
diethylthiambuten- Diethyl (1-methyl-3,3-di-2-thienylallyl) azan
-N, N-diethyltryptamine (diethyltryptamine, DET) Diethyl [2-(indol-3-yl) ethyl] azan
-dihydroetorphine
(18 ,19 -Dihydroetorphine)
(5R, 6R, 7R, 14R) -4, 5α-epoxy-7α-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethanomorphinan-3-ol
dimenoxadol- (2-dimethylaminoethyl) [(ethoxy) (diphenyl) acetate]
DimepheptanolMethadol 6-dimethylamino-4,4-diphenyl-heptan-3-ol
-Dimethoxyamfetamine (DMA) 1-(2,5-Dimethoxyphenyl) propan-2-ylazan
-Dimethoxyethylamfetamine (DOET) 1-(4-ethyl-2,5-dimethoxyphenyl) propan-2-ylazan
-Dimethoxymethamfetamine (DMMA) 1-(3,4-dimethoxyphenyl) -N-methylpropan-2-amine
-Dimethoxymethylamfetamine (DOM, STP) (RS) -1-(2,5-dimethoxy-4-methylphenyl) propane-2-ylazane
-Dimethylheptyltetrahydrocannabinol (DMHP) 6,6,9-Trimethyl-3-(3-methyl-octane-2-yl)-7,8,9, 10-tetra-hydro-6H-benzo (c) chromen-1-ol
dimethylthiambuten-Dimethyl (1-methyl-3,3-di-2-thienylallyl) Azan
-N, N-Dimethyltryptamine (Dimethyltryptamine, DMT)[2-(Indol-3-yl) ethyl] dimethyl-azan
dioxaphetyl butyrate- Ethyl-(4-morpholino-2,2-diphenylbutanoate)
Dipipanon- 4,4-diphenyl-6-piperidinoheptan-3-one
-DOC 1-(4-chloro-2,5-dimethoxyphenyl) propan-2-ylazan
Drotebanol- 3,4-Dimethoxy-17-methyl-morphinan-6ß, 14-diol
-N-ethylbuphedron
(NEB)
2-(Ethylamino) -1-phenylbutan-1-on
-4-Ethylmethcathinon
(4-EMC)
1-(4-Ethylphenyl) -2-(methylamino) propan-1-one
ethylmethylthiambuten- (ethyl) (methyl) (1-methyl-3,3-di-2-thienylallyl) azan
-ethylon
(bk-MDEA, MDEC)
1-(1,3-Benzodioxol-5-yl) -2-(ethylamino) propan-1-on
-ethylpiperidylbenzilate (1-ethyl-3-piperidyl) benzilate
EticyclidinPCE (ethyl (1-phenylcyclohexyl) azan
Etonitazen- {2-[2-(4-ethoxybenzyl) -5-nitrobenzimidazol-1-yl] ethyl} diethylazane
Etoxeridin- Ethyl {1-[2-(2-hydroxyethoxy) ethyl] -4-phenylpiperidine-4-carboxylate}
Etryptamineα-ethyltryptamine 1-(Indol-3-yl) butan-2-ylazan
-FLEA N-[1-(1,3-Benzodioxol-5-yl) propane-2-yl]-N-methyl-hydroxylamine
-4-Fluoramfetamine (4-FA, 4-FMP) (RS) -1-(4-Fluorophenyl) propan-2-amine
-ρ-Fluorfentanyl N-(4-Fluorophenyl) -N-(1-phenethyl-4-piperidyl) propanamide
-2-Fluoromethamfetamine
(2-FMA)
1-(2-fluorophenyl) -N-methylpropan-2-amine
-3-Fluoromethamfetamine
(3-FMA)
1-(3-Fluorophenyl) -N-methylpropan-2-amine
Furethidin- Ethyl {4-phenyl-1-[2-tetra-hydrofurfuryloxy) ethyl] piperidine-4-carboxylate}
-Heroin
(Diacetylmorphine, Diamorphine)- with the exception of diamorphine to the purposes specified in Annexes II and III-
[(5R, 6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diyl] diacetate
Hydromorphinol14 -Hydroxydihydromorphine4,5α-Epoxy-17-methyl-morphinan-3, 6α, 14-triol
-N-hydroxyamfetamine (NOHA)N-(1-phenylpropan-2-yl) hydroxylamine
- ß-HydroxyfentanylN-[1-(2-hydroxy-2-phenyl-ethyl)-4-piperidyl]-N-phenylpropanamide
-Hydroxymethylenedioxyamfetamine (N-hydroxy-MDA, MDOH)N-[1-(1,3-benzodioxol-5-yl) propan-2-yl] hydroxylamine
-β-hydroxy-3-methyl-fentanyl (Ohmefentanyl)N-[1-(2-hydroxy-2-phenyl-ethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide
Hydroxypethidine-ethyl [4-(3-hydroxyphenyl) -1-methylpiperidine-4-carboxylate]
-25I-NBOMe
(2C-I-NBOMe)
2-(4-lod-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
LefetaminSPA[(R) -1,2-Diphenylethyl] dimethylazan
Levomethorphan-(9R, 13R, 14R) -3-methoxy-17-methylmorphinan
Levophenacylmorphan-2-[(9R, 13R, 14R)-3-hydroxy-morphinan-17-yl]-1-phenyl-ethanon
Lofentanil-Methyl [(3R, 4S)-3-methyl-1-phenethyl-4-(N-phenyl-propanamido) piperidine-4-carboxylate]
LysergidN, N-Diethyl-D-lysergamide (LSD, LSD-25)N, N-diethyl-6-methyl-9, 10-didehydroergolin-8β-carboxamide
-MAL3,5-Dimethoxy-4-(2-methyl-allyloxy) phenethylazan
-MBDB[1-(1,3-Benzodioxol-5-yl) butan-2-yl] (methyl) azan
- Mebroqualon3-(2-bromophenyl) 2-methyl-quinazolin-4 (3H)-on
Mecloqualon-3-(2-chlorophenyl)-2-methyl-quinazolin-4 (3H)-on
-mescalin 3,4,5-Trimethoxyphenethylazan
Metazocin- 3,6, 11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
-Methcathinon (Ephedron) 2-methylamino-1-phenylpropan-1-on
-Methiopropamin (MPA) N-methyl-1-(thiophen-2-yl) propan-2-amine
-Methoxetamin (MXE) 2-(Ethylamino) -2-(3-methoxyphenyl) cyclohexanone
-methoxyamfetamine (PMA) 1-(4-methoxyphenyl) propan-2-ylazane
-5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT) Diisopropyl [2-(5-methoxyindol-3-yl) ethyl] azan
-5-methoxy-DMT (5-MeO-DMT) [2-(5-Methoxyindol-3-yl) ethyl] dimethylazan
-- (2-methoxyethyl) (1-phenyl-cyclohexyl) azan
-methoxymetamfetamine (PMMA) [1-(4-methoxyphenyl) propan-2-yl] (methyl) azan
-methoxymethylenedioxyamfetamine (MMDA) 1-(7-methoxy-1,3-benzodioxol-5-yl) propane-2-ylazane
-- (3-methoxypropyl) (1-phenyl-cyclohexyl) azan
-methylaminorex (4-methylaminorex) 4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-ylazane
-4-Methylbuphedron
(4-MeMABP)
2-(methylamino) -1-(4-methylphenyl) butan-1-one
Methyldesorphine- 4, 5α-Epoxy-6, 17-dimethyl-morphin-6-en-3-ol
Methyldihydromorphin- 4, 5α-Epoxy-6, 17-dimethyl-morphinan-3,6α-diol
-methylenedioxyethylamfetamine (N-ethyl-MDA, MDE, MDEA) [1-(1,3-Benzodioxol-5-yl) propan-2-yl] (ethyl) azan
-methylenedioxymetamfetamine (MDMA) [1-(1,3-Benzodioxol-5-yl) propan-2-yl] (methyl) azan
-α-methylfentanyl N-phenyl-N-[1-(1-phenylpropan-2-yl)-4-piperidyl] propanamide
-3-Methylfentanyl (Mefentanyl) N-(3-methyl-1-phenethyl-4-piperidyl) -N-phenylpropanamide
-methylmethaqualon 3-(2,4-Dimethylphenyl)-2-methyl-quinazolin-4 (3H) on
-3-Methylmethcathinon
(3-MMC)
2-(methylamino) -1-(3-methylphenyl) propan-1-one
-4-Methylmethcathinon
(Mephedron)
1-(4-methylphenyl) -2-methylaminopropan-1-one
-methylphenylpropionoxypiperidin (MPPP) (1-Methyl-4-phenyl-4-piperidyl) propionate
-methyl-3-phenylpropylamine (1M-3PP) (methyl) (3-phenylpropyl) azan
-methylphenyltetrahydropyridine (MPTP) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-methylpiperidylbenzilate (1-Methyl-3-piperidyl) benzilate
-4-methylthioamfetamine (4-MTA) 1-[4-(Methylsulfanyl) phenyl] propan-2-ylazan
-α-methylthiofentanyl N-phenyl-N-{1-[1-(2-thienyl) propane-2-yl]-4-piperidyl} propanamide
-3-Methylthiofentanyl N-{3-methyl-1-[2-(2-thienyl) ethyl]-4-piperidyl}-N-phenyl-propanamide
-α-methyltryptamine (α-MT) 1-(Indol-3-yl) propan-2-ylazan
Metopon5-Methyldihydromorphinon 4, 5α-epoxy-3-hydroxy-5, 17-dimethylmorphinan-6-on
Morpheridin- Ethyl (1-(2-morpholinoethyl) -4-phenylpiperidine-4-carboxylate)
-Morphin-N-oxide (5R, 6S) -4,5-epoxy-3,6-dihydroxy-17-methylmorphin-7-en-17-oxide
MyrophinMyristylbenzylmorphin (3-Benzyloxy-4, 5α-epoxy-17-methylmorphin-7-en-6-yl) tetradecanoate
Nicomorphin3,6-Dinicotinoylmorphin 4, 5α-Epoxy-17-methyl-morphin-7-en-3,6α-diyl) dinicotinate
Noracymethadol- (6-Methylamino-4,4-diphenyl-heptan-3-yl) acetate
NorcodeineN-Desmethylcodeine 4, 5α-Epoxy-3-methoxy-morphin-7-en-6α-ol
Norlevorphanol(-) 3-hydroxymorphinan (9R, 13R, 14R) -Morphinan-3-ol
NormorphinDesmethylmorphin 4, 5α-epoxymorphin-7-en-3,6α-diol
Norpipanon- 4,4-diphenyl-6-piperidinohexan-3-one
-Parahexyl 3-Hexyl-6,6,6,9-trimethyl-7,8,9, 10-tetrahydro-6H-benzo [c] chromen-1-ol
-PCPr (1-phenylcyclohexyl) (propyl) azan
-Pentylon
(bk-MBDP)
1-(1,3-Benzodioxol-5-yl) -2-(methylamino) pentan-1-one
Phenadox- 6-morpholino-4,4-diphenyl-heptan-3-one
phenampromid- N-phenyl-N-(1-piperidinopropan-2-yl) propanamide
Phenazocin- 6, 11-Dimethyl-3-phenethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
PhencyclidinPCP 1-(1-phenylcyclohexyl) piperidine
-phenethylphenylacetoxypipederidine (PEPAP) (1-phenethyl-4-phenyl-4-piperidyl) acetate
-phenethylphenyltetrahydropyridine (PEPTP) 1-phenethyl-4-phenyl-1,2,3,6-tetrahydropyridine
Phenpromethamine1-Methylamino-2-phenyl-propane (PPMA) (methyl) (2-phenylpropyl) azan
Phenomorphan- 17-phenethylmorphinan-3-ol
phenoperidin-ethyl [1-(3-hydroxy-3-phenyl-propyl)-4-phenylpiperidine-4-carboxylate]
Piminodin- Ethyl [1-(3-anilinopropyl) -4-phenylpiperidine-4-carboxylate]
-PPP 1-phenyl-2-(pyrrolidin-1-yl) propan-1-one
Proheptazin- (1,3-dimethyl-4-phenylazepan-4-yl) propionate
Properidin- isopropyl (1-methyl-4-phenyl-piperidin-4-carboxylate)
-psilocin (psilotsin) 3-(2-Dimethylaminoethyl) indol-4-ol
-Psilocin-(eth) 3-(2-diethylaminoethyl) indol-4-ol
Psilocybin- [3-(2-Dimethylaminoethyl) indol-4-yl] dihydrogen phosphate
-Psilocybin-(eth) [3-(2-diethylaminoethyl) indol-4-yl] dihydrogen phosphate
-- 2-(pyrrolidin-1-yl) -1-(p-tolyl) propan-1-one
Racemethorphan- (9RS, 13RS, 14RS) -3-methoxy-17-methylmorphinan
RolicyclidinPHP (PCPy) 1-(1-phenylcyclohexyl) pyrrolidine
-Salvia divinorum
(plants and plant parts)
-
TenamfetamineMethylenedioxyamfetamine (MDA) (RS) -1-(1,3-Benzodioxol-5-yl) propan-2-ylazan
TenocyclidinTCP 1-[1-(2-thienyl) cyclohexyl] piperidine
tetrahydrocannabinole, the following isomers and their stereochemical variants:
-Δ6a (10a) -tetrahydrocannabinol
(Δ6a (10a) -THC)
6,6,9-trimethyl-3-pentyl-7,8,9, 10-tetrahydro-6H-benzo [c] chromen-1-ol
-Δ6a-tetrahydrocannabinol
(Δ6a-THC)
(9R, 10aR)-6,6,9-Trimethyl-3-pentyl-8,9, 10, 10a-tetra-hydro-6H-benzo [c] chromen-1-ol (6aR, 9R, 10aR) -6,6,9-trimethyl-3-pentyl-6a, 9, 10, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
-Δ7-tetrahydrocannabinol
(Δ7-THC)
- Δ8-tetrahydrocannabinol
(Δ8-THC)
(6aR, 10aR)-6,6,9-Trimethyl-3-pentyl-6a, 7, 10, 10a-tetra-hydro-6H-benzo [c] chromene 1-ol (6aR) -6,6,9-trimethyl-3-pentyl-6a, 7,8,9-tetrahydro-6H-benzo [c] chromen-1-ol
-Δ10 -tetrahydrocannabinol
(Δ10-THC)
-Δ9 (11) -tetrahydrocannabinol
(Δ9 (11) -THC)
(6aR, 10aR) -6,6-dimethyl-9-methylen-3-pentyl-6a, 7,8,9, 10, 10a-hexahydro-6H-benzo [c] chromen-1-ol
-Thenylfentanyl N-phenyl-N-(1-thenyl-4-piperidyl) propanamide
-Thienoamfetamine
(Thiopropamin)
1-(Thiophen-2-yl) propan-2-amine
-Thiofentanyl N-phenyl-N-{1-[2-(2-thienyl) ethyl]-4-piperidyl} propanamide
Trimeperidin- (1,2,5-trimethyl-4-phenyl-4-piperidyl) propionate
-Trimethoxyamfetamine (TMA) 1-(3,4,5-Trimethoxyphenyl) propan-2-ylazan
-2,4,5-Trimethoxyamfetamine (TMA-2) 1-(2,4,5-Trimethoxyphenyl) propane-2-ylazane
-
the esters, ethers and Molecule compounds of the substances listed in this Appendix if they are not listed in another plant and the existence of such esters, ethers and molecular compounds is possible;
-
the salts of the substances listed in this Appendix, if the existence of such salts is possible;
-
the Preparations of the substances listed in this Appendix if they do not
a)
without the substance or in the human or animal body, are used exclusively for diagnostic or analytical purposes and their content of one or more stunning agents does not exceed 0.001 of the hundred or the substances in the preparations isotopenmodified or
b)
are especially excluded;
-
the stereoisomers the substances listed in this or any other Annex if they are to be used as a narcotic agent;
-
Substances pursuant to § 2 (1) (1) Point (b) to (d) with substances listed in this or any other plant, and the biological materials suitable for the reproduction or extraction of substances in accordance with Article 2 (1) (1) (b) to (d), if an abuse is used for noise purposes
Non-official table of contents

Annex II (to § 1 para. 1)
(marketable but non-prescription)
Anaesthesials)

(Fundstelle: BGBl. I 2001, 1187-1189;
bzl of the individual amendments, cf. Footnote)

Column 1 contains the International Nonproprietary Names (INN) of the World Health Organization. In the name of a substance, the INN takes precedence over all other designations.
Column 2contains other non-protected Names of substances (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They are therefore to be used in conjunction with the designation in column 3.
Column 3contains the chemical name of the chemical according to the Nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no label is listed in column 1 or column 2, then the column 3 is to be used.
INN other unprotected or TrivialNames Chemical Names (IUPAC)
-AB-CHMINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(cyclohexylmethyl) -1H-indazol-3-
carboxamide
- AB-FUBINACAN-(1-amino-3-methyl-1-oxobutan-
2-yl) -1-[(4-fluorophenyl) methyl] -1H-
indazol-3-carboxamide
- AB-PINACAN-(1-amino-3-methyl-1-oxobutan-
2-yl) -1-pentyl-1H-indazol-3-carboxamide
- 1-Adamantyl (1-pentyl-1H-indol-3-yl) methanone(Adamantan-1-yl) (1-pentyl-1H-indol-3-yl) methanone
- AH-7921
(Doxylam)
3,4-Dichlor-N-{[1-(dimethylamino)
cyclohexyl] methyl} benzamide
- AKB-48 (APINACA)N-(Adamantan-1-yl) -1-pentyl-1H-indazol-3-carboxamide
-AKB-48F N-(adamantan-1-yl) -1-(5-fluoropentyl) -1H-indazol-3-carboxamide
-AM-694 [1-(5-Fluorpentyl) -1H-indol-3-yl] (2-iodophenyl) methanone
-AM-1220 {1-[(1-Methylpiperidin-2-yl) methyl] -1H-indol-3-yl} (naphthalen-1-yl) methanone
-AM-1220-Azepan [1-(1-Methylazepan-3-yl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
-AM-2201 [1-(5-Fluorpentyl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
-AM-2232 5-[3-(naphthalene-1-carbonyl) -1H-indol-1-yl] pentane nitrile
-AM-2233 (2-Iodphenyl) {1-[(1-methylpiperidin-2-yl) methyl] -1H-indol-3-yl} methanone
Amfetaminil- (phenyl) [(1-phenylpropan-2-yl) amino] acetonitrile
amineptin- 7-(10, 11-dihydro-5H-dibenzo [a, d] [7] annulen-5-ylamino) heptanoic acid
Aminorex- 5-Phenyl-4,5-dihydro-1,3-oxazol-2-ylazane
-5-APB 1-(benzofuran-5-yl) propane-2-amine
-6-APB1-(benzofuran-6-yl) propane-2-amine
-APICA
(SDB-001, 2NE1)
N-(adamantan-1-yl) -1-pentyl-1H-
indole-3-carboxamide
-BB-22
(QUCHIC)
Chinolin-8-yl [1-(cyclohexylmethyl) -1H-indole-3-carboxylate]
-benzylpiperazine (BZP)1-benzylpiperazine
- Buphedron2-(methylamino) -1-phenylbutan-1-one
Butalbital- 5-Allyl-5-isobutylbarbituric acid
-Butobarbital 5-butyl-5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trione
-butylon1-(benzo [d] [1, 3] dioxol-5-yl) -2-
(methylamino) butan-1-on
-Cannabis
(marijuana, plants and plant parts of the plants belonging to the genus Cannabis)
-
-if it is intended for the production of medical-purpose preparations-
CetobemidonKetobemidon1-[4-(3-hydroxyphenyl) -1-methyl-4-piperidyl] propan-1-one
-meta-chlorophenylpiperazine (m-CPP)1-(3-chlorophenyl) piperazine
- d-CocaineMethyl (3ß-(benzoyloxy) tropan-2alpha-carboxylate)
-CP 47,497 (cis-3-[4-(1,1-dimethylheptyl) -2-hydroxyphenyl] cyclohexanol)5-(1,1-dimethylheptyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
- CP 47 ,497-C6-Homolog (cis-3-[4-(1,1-dimethylhexyl) -2-hydroxyphenyl]-cyclohexanol)5-(1,1-dimethylhexyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl]-phenol
-CP 47 ,497-C8-Homolog (cis-3-[4-(1,1-Dimethyloctyl) -2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethyloctyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
-CP 47 ,497-C9-Homolog (cis-3-[4-(1,1-dimethylnonyl) -2-hydroxyphenyl] cyclohexanol)5-(1,1-dimethylnonyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
Cyclobarbital-5-(cyclohex-1-en-1-yl) -5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trione
- Desoxypipradrol
(2-DPMP)
2-(diphenylmethyl) piperidine
- Dextromethadone(S) -6-dimethylamino-4,4-diphenylheptan-3-one
Dextromoramide- (S) -3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Dextropropoxyphen- [(2S, 3R) -4-dimethylamino-3-methyl-1,2-diphenylbutan-2-yl] propionate
-Diamorphin [(5R, 6S) -4,5-epoxy-17-methylmorphin-7-en-3,6-diyl] diacetate
-
insofar as it is intended for preparation for medical purposes-
difenoxin-1-(3-Cyan-3,3-diphenylpropyl) -4-phenylpiperidine-4-carboxylic acid
-
except in preparations that do not have any other substance in Annexes I to III, up to 0.5 mg difenoxin, calculated as base, and, based on this amount, at least 5 of the hundreds of atropin sulphate contained-
- dihydromorphine4,5α-epoxy-17-methylmorphinan-3,6α-diol
-dihydrothebain 4, 5α-epoxy-3,6-dimethoxy-17-methylmorphin-6-en
-Dimethocain
(DMC, Larocain)
(3-diethylamino-2,2-dimethylpropyl) -4-aminobenzoate
-2,5-Dimethoxy-4-iodamfetamine
(DOI)
1-(4-Iod-2,5-dimethoxyphenyl) propan-2-amine
-3,4-Dimethylmethcathinon (3 ,4-DMMC) 1-(3,4-Dimethylphenyl) -2-(methylamino) propan-1-one
Diphenoxylate- Ethyl [1-(3-cyan-3,3-diphenylpropyl) -4-phenylpiperidine-4-carboxylate]
-
except in preparations containing up to 0.25 mg of diphenoxylate, calculated as the base, and without any other substance in Annexes I to III up to 0.25 of the hundred or per divided form, related to these amounts, at least 1 of the hundred atropinsulfate contained-
-4,4 ' -DMAR
(para-methyl-4-methylaminorex)
4-methyl-5-(4-methylphenyl) -4,5-
dihydro-1,3-oxazol-2-amine
-EAM-2201
(5-fluoro-JWH-210)
(4-Ethylnaphthalin-1-yl) [1-(5-fluoropentyl) -1H-indol-3-yl] methanone
-Ecgonin 3β-hydroxytropane-2β-carboxylic acid
-Erythroxylum coca
(plants and plant parts of the type erythroxylum coca-including the Varietties bolivianum, spruceanum and novogranatense-related plants)
-
-Ethcathinon (RS) -2-(Ethylamino) -1-
phenylpropan-1-on
Ethchlorvynol- 1-chloro-3-ethylpent-1-en-4-in-3-ol
Ethinamat- (1-Ethinylcyclohexyl) carbamate
-3-O-ethylmorphin
(ethylmorphine)
4, 5α-epoxy-3-ethoxy-17-methylmorphin-7-en-6α-ol
-
except in preparations containing up to 100 mg of ethylmorphine, calculated as base, without any other substance in Annexes I to III, up to 2.5 per cent or per divided form. -
-ethylphenidateethyl [2-(phenyl) -2-(piperidin-2-yl) acetate]
EtilamfetamineN-ethylamphetamine(ethyl) (1-phenylpropan-2-yl) azan
- 5F-ABICA
(5F-AMBICA, 5-fluoro-ABICA, 5-Fluoro-AMBICA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(5-fluoropentyl) -1H-indole-3-carboxamide
-5F-AB-PINACA
(5-fluoro-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(5-fluoropentyl) -1H-indazol-3-
carboxamide
-5F-AMB
(5-Fluoro-AMB)
Methyl { 2- [ 1- (5-fluoropentyl) -1H-indazol-
3-carboxamido] -3-methylbutanoate }
-FDU-PB-22 naphthalen-1-yl {1 [(4-fluorophenyl) methyl] -1H-indole-3-carboxylate}
Fencamfamin- N-ethyl-3-phenylbicyclo [2.2.1] heptan-2-amine
-Flephedron (4-Fluormethcathinon, 4-FMC) 1-(4-fluorophenyl) -2-(methylamino) propan-1-one
-4-Fluoromethamfetamine (4-FMA) 1-(4-Fluorophenyl) -N-methylpropan-2-amine
-3-Fluormethcathinon (3-FMC) 1-(3-Fluorophenyl) -2-(methylamino) propan-1-one
-5-Fluorpentyl-JWH-122 (MAM-2201) [1-(5-Fluorpentyl) -1H-indol-3-yl] (4-methylnaphthalen-1-yl) methanone
-p-Fluorophenylpiperazine (p-FPP) 1-(4-Fluorophenyl) piperazine
-4-Fluortropacocain 3-(4-fluorobenzoyloxy) tropane
-5-fluoro-UR-144 (XLR-11)[1-(5-fluoropentyl) -1H-indol-3-yl] (2 ,2,3,3-tetramethylcyclopropyl) methanone
-5F-PB-22
(5F-QUPIC)
Chinolin-8-yl [1-(5-fluoropentyl) indole-3-carboxylate]
-5F-SDB-006 N-Benzyl-1-(5-fluoropentyl) -1H
-indole-3-carboxamide
-FUB-PB-22 Chinolin-8-yl {1-[(4-fluorophenyl) methyl] -1H-indole-3-carboxylate}
Glutethimide- 3-ethyl-3-phenylpiperidin-2,6-dione
-Isocodeine 4, 5α-epoxy-3-methoxy-17-methylmorphin-7-en-6ß-ol
isomethadon- 6-dimethylamino-5-methyl-4,4-diphenylhexan-3-one
-JWH-007 (2-methyl-1-pentyl-1H-indol-3-yl) (naphthalen-1-yl) methanone
-JWH-015 (2-methyl-1-propyl-1H-indol-3-yl) (naphthalen-1-yl) methanone
-JWH-018
(1-Pentyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
-JWH-019
(1-Hexyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-hexyl-1H-indol-3-yl) methanone
-JWH-073
(1-butyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-butyl-1H-indol-3-yl) methanone
-JWH-081 (4-methoxynaphthalen-1-yl) (1-
pentyl-1H-indol-3-yl) methanone
-JWH-122 (4-methylnaphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
-JWH-200 [1-(2-morpholinoethyl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
-JWH-203 2-(2-chlorophenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
-JWH-210 (4-ethylnaphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
-JWH-250
(1-Pentyl-3-(2-methoxy-phenylacetyl) indole)
2-(2-methoxyphenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
-JWH-251 2-(2-methylphenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
-JWH-307 [5-(2-fluorophenyl) -1-pentyl-1H-pyrrol-3-yl] (naphthalen-1-yl) methanone
LevamfetamineLevamphetamin (R) -1-phenylpropan-2-ylazan
-Levmetamfetamine (Levometamfetamine) (R)-(methyl) (1-phenylpropan-2-yl) azan
Levomoramid- (R) -3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Levorphanol- (9R, 13R, 14R) -17-methylmorphinan-3-ol
Mazindol- 5-(4-chlorophenyl) -2,5-dihydro-3H-imidazole [2,1-a] isoindol-5-ol
Mefenorex- 3-chloro-N-(1-phenylpropane-2-yl) propane-1-amine
Meprobamat- (2-methyl-2-propylpropane-1,3-diyl) dicarbamate
mesocarb- (phenylcarbamoyl) [3-(1-phenylpropan-2-yl) -1,2,3-oxadiazol-3-ium-5-yl] azanid
metamfetaminemethamphetamine (2S) -N-methyl-1-phenylpropan-2-amine
(RS) -MetamfetamineMetamfetaminracemat (RS)-(methyl) (1-phenylpropan-2-yl) azan
-methadone intermediate (Premethadone) 4-dimethylamino-2,2-diphenylpentenitrile
Methaqualon- 2-methyl-3-(2-methylphenyl) quinazolin-4 (3H)-on
-Methedron (4-methoxymethcathinon, PMMC) 1-(4-methoxyphenyl) -2-(methylamino) propan-1-one
-p-methoxyethylamfetamine (PMEA) N-ethyl-1-(4-methoxyphenyl) propan-2-amine
-4-Methylamfetamine 1-(4-methylphenyl) propan-2-amine
-methylbenzylpiperazine (MBZP) 1-benzyl-4-methylpiperazine
-3,4-Methylendioxypyrovaleron (MDPV) 1-(Benzo [d] [1, 3] dioxol-5-yl) -2-(pyrrolidin-1-yl) pentan-1-one
-4-Methylethcathinon (4-MEC) 2-(ethylamino) -1-(4-methylphenyl) propan-1-one
-Methylon (3 ,4-Methylenedioxy-N-methcathinon, MDMC) 1-(Benzo [d] [1, 3] dioxol-5-yl) -2-(methylamino) propan-1-on
(RS; SR) -Methylphenidat- Methyl [(RS; SR) (phenyl) (2-piperidyl) acetate]
Methyprylon- 3,3-diethyl-5-methylpiperidine-2,4-dione
-poppy straw concentrate
(which is used in the processing of plants and plant parts of the species) Papaver somniferum for concentration of alkaloids)
-
-Moramide intermediate (Premoramide)3-Methyl-4-morpholino-2,2-diphenylbutanoic acid
-MT-45 1-cyclohexyl-4-(1,2-diphenylethyl)
piperazine
-Naphyron (naphthylpyrovalerone) 1-(naphthalen-2-yl) -2-(pyrrolidin-1-yl) pentan-1-one
Nicocodin6-Nicotinoylcodeine (4, 5α-epoxy-3-methoxy-17-methylmorphin-7-en-6α-yl) nicotinate
Nicodicodin6-Nicotinoyldihydrocodeine (4, 5α-epoxy-3-methoxy-17-methylmorphinan-6α-yl) nicotinate
-Oripavin 4, 5α-epoxy-6-methoxy-17-methylmorphina-6,8-dien-3-ol
Oxymorphon14 -Hydroxydihydromorphinon 4, 5α-epoxy-3, 14-dihydroxy-17-methylmorphinan-6-one
-Papaver bracteatum
(plants and parts of plants, excluding the seeds that are used for the Species Papaver bracteatum belonging plants)
-
-
except for zierpurposes-
-PB-22
(QUPIC)
Chinolin-8-yl (1-pentylindol-3-carboxylate)
-Pentedron 2-(methylamino) -1-phenylpentan-1-one
-Pethidine Interproduct A (Prepethidin) 1-methyl-4-phenylpiperidine-4-carbonitrile
-Pethidine intermediate B (Norpethidin) Ethyl (4-phenylpiperidin-4-carboxylate)
-Pethidine intermediate C (Pethidinic acid) 1-methyl-4-phenylpiperidin-4-carboxylic acid
phendimetrazine- (2S, 3S) -3,4-dimethyl-2-phenylmorpholine
phenmetrazine- 3-methyl-2-phenylmorpholine
Pholcodinmorpholinylethylmorphin 4, 5α-epoxy-17-methyl-3-(2-morpholinoethoxy) morphin-7-en-6α-ol
-
except in preparations without a further substance in Annexes I to III as a solution up to 0.15 per hundred, but not more than 150 mg per unit of package, or per unit Form up to 20 mg Pholcodin, calculated as base, included-
Propiram- N-(1-piperidinopropan-2-yl) -N-(2-pyridyl) propanamide
Pyrovaleron- 2-(pyrrolidin-1-yl) -1-(ρ-tolyl) pentan-1-one
-α-pyrrolidinovalerophenone (α-PVP) 1-phenyl-2-(pyrrolidin-1-yl) pentan-1-one
Racemoramide- (RS) -3-Methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Racemorphan- (9RS, 13RS, 14RS) -17-methylmorphinan-3-ol
-RCS-4 (4-methoxyphenyl) (1-pentyl-1H-indol-3-yl) methanone
-RCS-4 ortho-isomer (o-RCS-4) (2-methoxyphenyl) (1-pentyl-1H-indol-3-yl) methanone
-SDB-006 N-Benzyl-1-pentyl-1H-indol-3-
carboxamide
Secbutabarbitalbutabarbital 5-(Butan-2-yl) -5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trion
-STS-135
(5F-2NE1)
N-(Adamantan-1-yl) -1-(5-fluoropentyl) -1H-indole-3-carboxamide
-Δ9-tetrahydrocannabinol
(Δ9-THC)
6,6,9-trimethyl-3-pentyl-6a, 7,8, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
-tetrahydrothebain 4, 5α-epoxy-3,6-dimethoxy-17-methylmorphinan
Thebaconacetyldihydrocodeinon (4, 5α-epoxy-3-methoxy-17-methylmorphine-6-en-6-yl) acetate
-Thebain 4, 5α-epoxy-3,6-dimethoxy-17-methylmorphina-6,8-diene
-THJ-018
(JWH-018 Indazol-Analog)
(naphthalen-1-yl) (1-pentyl-1H-indazole-
3-yl) methanone
-THJ-2201
(AM-2201 Indazol-analog)
[1-(5-Fluorpentyl) -1H-indazol-3-yl] (naphthalen-1-yl) methanone
cis-Tilidin- Ethyl [(1RS, 2RS) -2-dimethylamino-1-phenylcyclohex-3-enecarboxylate]
-3-trifluoromethylphenylpiperazine (TFMPP) 1-[3-(trifluoromethyl) phenyl] piperazine
-UR-144 (1-Pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone
Vinylbital- 5-Ethenyl-5-(pentan-2-yl) pyrimidine-2,4,6 (1H, 3H, 5H)-trion
Zipeprol- 1-methoxy-3-[4-(2-methoxy-2-phenylethyl) piperazin-1-yl] -1-phenylpropan-2-ol
-
the esters, ethers and molecular compounds of the substances listed in this Appendix as well as the esters and ethers of the substances listed in Appendix III, excluding gamma-hydroxybutyric acid (GHB) if they are not are listed in a different plant and the existence of such esters, ethers and molecular compounds is possible;
-
the salts of the substances listed in this Annex, if the existence of such salts is possible, as well as the salts and molecular compounds of the substances listed in Annex III, if the existence of such salts and molecular compounds is possible and if they are not medically, dental or veterinary ;
-
the preparations of the substances listed in this Appendix if they are not
a)
not being used on or in the human or animal body, only diagnostic or analytical purposes, and their content of one or more narcotic agents, in the case of lyophilisates and corresponding mixtures of substances to be used in the ready-to-use solution, in each case not exceeding 0.01 of the hundred, or the substances in the Preparations isotopenmodified or
b)
are especially excluded.
unofficial table of contents

Appendix III (to § 1 para. 1)
marketable and potable narcotics

(find: BGBl. I 2001, 1189-1195;
of the individual amendments, cf. Footnote)
Column 1 contains the International Nonproprietary Names (INN) of the World Health Organization. In the name of a substance, the INN takes precedence over all other designations.
Column 2contains other non-protected Names of substances (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They are therefore to be used in conjunction with the designation in column 3.
Column 3contains the chemical name of the chemical according to the Nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no label is listed in column 1 or column 2, then the column 3 is to be used.
INN other unprotected or TrivialNames Chemical Names (IUPAC)
Alfentanil- N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl) ethyl] -4-methoxymethyl-4-piperidyl} -N-phenylpropanamide
Allorbarbital-5,5-Diallylbarbituric acid
Alprazolam- 8-Chloro-1-methyl-6-phenyl-4H-[1,2, 4] triazolo [4,3-a] [1, 4] benzodiazepine
-
except in preparations that contain up to 1 mg of alprazolam without a further substance in Annexes I to III
Amfepramondiethylpropion2-diethylamino-1-phenylpropan-1-on
-
except in preparations without delayed release of the active ingredient, which without any other substance of the plants I to III per divided form up to 22 mg, and in preparations with delayed release of active substance, which contain up to 64 mg of amfepramon, calculated as base, without any other substance in Annexes I to III, calculated as base
AmfetamineAmphetamin(RS) -1-phenylpropan-2-ylazan
Amobarbital-5-ethyl-5-isopentylbarbituric acid
Barbital-5,5-diethylbarbituric acid
-
except in preparations,
a)
without any other fabric of attachments I to III up to 10 from the hundred or
b)
without being used on or in the human or animal body, exclusively for diagnostic or analytical purposes and without a further substance in equipment I to III per pack unit not more than 25 g Barbital, calculated as acid, included-
Bromazepam- 7-bromo-5-(2-pyridyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations containing up to 6 mg bromazepam without a further substance in Annexes I to III-
Brotizolam-2-Bromo-4-(2-chlorophenyl) -9-methyl-6H-thieno [3,2-f] [1,2, 4] triazolo [4,3-a] [1, 4] diazepine
-
except in preparations without a further substance of the Attachments I to III up to 0.02 from the hundred or each divided form up to 0.25 mg of brotizolam-
Buprenorphine- (5R, 6R, 7R, 14S)-17-Cyclopropyl-methyl-4,5-epoxy-7-[(S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-6, 14-ethanomorphinan-3-ol
Camazepam-(7-Chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-enzodiazepin-3-yl) (dimethylcarbamate)
- Cannabis
(marijuana, plants and plant parts of the
plants belonging to the genus cannabis)
-
-only in Preparations approved as ready-made medicinal products-
Cathin(+) -Norpseudoephedrine (D-Norpseudoephedrin) (1S, 2S) -2-amino-1-phenylpropan-1-ol
-
except in preparations without a further substance in Annexes I to III up to 5 of the hundred as a solution, but not more than 1 600 mg per unit of package or per unit Form up to 40 mg of cathin, calculated as base, contain-
chlordiazepoxide- 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide
-
except in preparations which contain up to 25 mg of chlordiazepoxide in each form, without any other substance in Annexes I to III
Clobazam-7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,5-benzodiazepin-2,4 (5H)-dione
-
except in preparations that do not have any other substance in Annexes I Up to III depending on the form up to 30 mg of clobazam included-
Clonazepam- 5-(2-chlorophenyl) -7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
except in preparations which without a further substance in Annexes I to III up to 0.25 of the hundred as a drip solution, but not more than 250 mg per pack unit or per unit divided form up to 2 mg Clonazepam included-
Clorazepat- (RS) -7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
except in preparations containing up to 50 mg of units I to III, as dry matter only for parenteral use, up to 100 mg, without any other substance in Annexes I to III, clorazepate as a dipotassium salt-
Clotiazepam- 5-(2-chlorophenyl) -7-ethyl-1-methyl-1,3-dihydro-2H-thieno [2,3-e] [1, 4] diazepin-2-one
except in preparations containing up to 20 mg clotiazepam without a further substance in Annexes I to III-
Cloxazolam-10-Chloro-11b-(2-chlorophenyl) -2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
-Cocaine (benzoylecgonine methyl ester)methyl [3ß-(benzoyloxy) tropan-2ß-carboxylate]
-Codeine (3-Methylmorphine)4,5α-epoxy-3-methoxy-17-methylmorphin-7-en-6α-ol
-
except in preparations which do not include any other substance in Annexes I to III to 2.5 from the hundred or per divided form, up to 100 mg of codeine, calculated as base. However, the rules governing the prescribing and dispensing of narcotic drugs shall apply to excluded preparations which are prescribed for persons dependent on stunted or alcohol-related persons. -
Delorazepam- 7-Chloro-5-(2-chlorophenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
DexamfetamineDexamphetamine (S) -1-phenylpropan-2-ylazan
Dexmethylphenidat- Methyl [(R, R) (phenyl) (2-piperidyl) acetate]
-Diamorphin [(5R, 6S) -4,5-epoxy-17-methylmorphin-7-en-3,6-diyl] diacetate
-
only in preparations allowed for substitution treatment-
Diazepam-7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations that do not include any other substance in Annexes I to III up to 1 of the hundred as Syrup or drip solution, but not more than 250 mg per pack unit, or per divided form, up to 10 mg of diazepam included-
dihydrocodeine-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
-
except in preparations that do not include any other substance in Annexes I to III up to 2.5 from the hundred or in each form, up to 100 mg of dihydrocodeine, calculated as base. However, the rules governing the prescribing and dispensing of narcotic drugs shall apply to excluded preparations which are prescribed for persons dependent on stunted or alcohol-related persons. -
Dronabinol- (6aR, 10aR) -6,6,9-trimethyl-3-pentyl-6a, 7,8, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
Estazolam- 8-chloro-6-phenyl-4H-[1,2, 4] triazolo [4,3-a] benzodiazepine
-
except in preparations that contain up to 2 mg of estazolam without a further substance in Annexes I to III
Ethylloflazepat-Ethyl [7-chloro-5-(2-fluorophenyl) -2-oxo-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylate]
Etizolam-4-(2-chlorophenyl) -2-ethyl-9-methyl-6H-thieno [3,2-f] [1,2, 4] triazolo [4,3-a] [1, 4] diazepine
Etorphin-(5R, 6R, 7R, 14R) -4,5-epoxy-7-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethenomorphinan-3-ol
Fenetyllin-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino) ethyl] -3,7-dihydro-2H-purin-2,6 (1H)-dione
Fenproportionex-(RS) -3-(1-phenylpropan-2-ylamino) propannitrile
-
except in preparations that do not have any other substance in Annexes I to III, up to 11 mg Fenproportionex, calculated as base, included-
Fentanyl- N-(1-phenethyl-4-piperidyl) -N-phenylpropanamide
Fludiazepam- 7-Chloro-5-(2-fluorophenyl) -1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Flunitrazepam- 5-(2-Fluorophenyl) -1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Flurazepam- 7-Chloro-1-(2-diethylaminoethyl) -5-(2-fluorophenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
except in preparations that contain up to 30 mg of flurazepam without a further substance in Annexes I to III
Halazepam-7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations that do not have any other substance in Annexes I up to III per split form up to 120 mg of halazepam-
Haloxazolam- 10-Brom-11b-(2-fluorophenyl) -2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
Hydrocodondihydrocodeinone 4, 5α-epoxy-3-methoxy-17-methylmorphinan-6-on
Hydromorphondihydromorphinon 4, 5α-epoxy-3-hydroxy-17-methylmorphinan-6-one
-γ-hydroxybutyric acid (GHB) 4-Hydroxybutanoic acid
-
except in preparations for injection, which without a further substance in Annexes I to III, up to 20 per cent and per divided form, up to 2 g gamma-hydroxybutyric acid, calculated as acid, contain-
Ketazolam- 11-chloro-2,8-dimethyl-12b-phenyl-8, 12b-dihydro-4H-[1, 3] oxazino [(3,2-d] [1, 4] benzodiazepin-4,7 (6H)-dione
-
except in preparations that do not have any other substance in Annexes I to III, up to to 45 mg Ketazolam included-
LevacetylmethadolLevomethadyl acetate (LAAM) [(3S, 6S) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
Levomethadon- (R) -6-dimethylamino-4,4-diphenylheptan-3-one
Lisdexamfetamine- (2S)-2,6-Diamino-N-[(2S)-1-phenylpropane-2-yl] hexanamide
Loprazolam- 6-(2-chlorophenyl) -2-[(Z) -4-methylpiperazin-1-ylmethylene] -8-nitro-2,4-dihydro-1H-imidazo [1,2-a] [1, 4] benzodiazepin-1-one
-
except in preparations that do not have any other substance in Annexes I to III, up to to 2.5 mg Loprazolam included-
Lorazepam- (RS) -7-Chloro-5-(2-chlorophenyl) -3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one
except in preparations containing up to 2.5 mg of lorazepam free of any other substance in Annexes I to III
Lormetazepam-7-Chloro-5-(2-chlorophenyl) -3-hydroxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations without a further substance of the Annexes I to III in each form divided up to 2 mg Lormetazepam-
Medazepam- 7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine
except in preparations containing up to 10 mg medazepam without a further substance in Annexes I to III-
Methadon-(RS) -6-dimethylamino-4,4-diphenylheptan-3-one
methylphenidat-methyl [(RS; RS) (phenyl) (2-piperidyl) acetate]
methylphenobarbital Mephobarbital(RS)-5-ethyl-1-methyl-5-phenyl-barbituric acid
-
except in preparations that do not have any other substance in Annexes I to III, up to to 200 mg methylphenobarbital, calculated as acid, included-
Midazolam- 8-chloro-6-(2-fluorophenyl) -1-methyl-4H-imidazo [1,5-a] [1, 4] benzodiazepine
-
other than in preparations containing up to 0.2 per cent or per divided form up to 15 mg of midazolam without any other substance in Annexes I to III -
-Morphin(5R, 6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diol
Nabilon- (6aRS, 10aRS) -1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl) -6, 6a, 7,8, 10, 10a-hexahydro-9H-benzo [c] chromen-9-one
Nimetazepam- 1-Methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Nitrazepam- 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations which, without a further substance in Annexes I to III, have a form of up to 0.5 per unit of drop, but not more than 250 mg per unit Package unit, or depending on the form, up to 10 mg of nitrazepam included-
Nordazepam- 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations which, without a further substance in Annexes I to III, have a form of up to 0.5 of the hundred as a drip solution, but not more than 150 mg per unit Package unit, or depending on the form, up to 15 mg Nordazepam included-
Normethadon- 6-dimethylamino-4,4-diphenyl-hexan-3-one
-Opium
(the tanned juice of the plants belonging to the species Papaver somniferum)
-
-
except in preparations produced according to a process technique described in the homeopathic part of the Pharmacopoeia, if the final concentration is the sixth decimal potency. not exceeding-
Oxazepam- 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
except in preparations that contain up to 50 mg of oxazepam without any other substance in Annexes I to III
Oxazolam-(2RS, 11bSR) -10-chloro-2-methyl-11b-phenyl-2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
-
except in preparations without a further substance of the Annexes I to III per divided form contain up to 20 mg oxazolam-
Oxycodon14 -Hydroxydihydrocodeinon 4, 5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
-Papaver somniferum
(plants and plant parts, excluding the seeds, the on the species Papaver somniferum (including the subspecies of setigerum)
-
-
except when the traffic is used with them (except for the cultivation) for ornamenting purposes, and if in the dried State of the state of the morphin is not more than 0.02 per cent; in this case, the legislation on anaesthesiation shall apply to the importation, exportation and transit-
-
except in preparations produced according to a process technique described in the homeopathic part of the Pharmacopoeia, if the final concentration is the fourth decimal potency. not exceeding-
-
except in preparations containing up to 0.015 of the Hundred Morphine, calculated as base, without any other substance from Annexes I to III; and which are composed of one or more other ingredients in such a way that the narcotic agent cannot be recovered by means of easily applicable procedures or in an extent which is dangerous to public health; -
Pemolin-2-Imino-5-phenyl-1,3-oxazolidin-4-one
-
except in preparations that do not have any other substance in Annexes I up to III per split form up to 20 mg of pemolin, calculated as base
Pentazocin- (2R, 6R, 11R) -6, 11-Dimethyl-3-(3-methylbut-2-en-1-yl) -1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
Pentobarbital- (RS) -5-Ethyl-5-(pentan-2-yl) barbituric acid
Pethidine- Ethyl (1-methyl-4-phenyl-piperidin-4-carboxylate)
-Phenazepam 7-bromo-5-(2-chlorophenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
Phenobarbital- 5-ethyl-5-phenylbarbituric acid
-
except in preparations containing up to 300 mg of phenobarbital, calculated as acid, without any other substance in Annexes I to III up to 10 per hundred or per divided form. -
Phentermin-2-benzylpropan-2-ylazan
-
except in preparations that do not have any other substance in Annexes I to III Split form up to 15 mg of Phentermin, calculated as base, included-
Pinazepam- 7-chloro-5-phenyl-1-(prop-2-in1-yl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
Pipradrol- Diphenyl (2-piperidyl) methanol
Piritramid- 1 '-(3-Cyan-3,3-diphenylpropyl) [1,4'-bipiperidine] -4 '-carboxamide
Prazepam- 7-Chloro-1-cyclopropylmethyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
except in preparations that contain up to 20 mg of Prazepam without a further substance in Annexes I to III
Remifentanil-Methyl {3-[4-methoxycarbonyl-4-(N-phenylpropanamido) piperidino] propanoate}
Secobarbital-5-Allyl-5-(pentan-2-yl) barbituric acid
Sufentanil-N-{4-methoxymethyl-1-[2-(2-thienyl) ethyl] -4-piperidyl} -N-phenylpropanamide
Tapentadol-3-[(2R, 3R) -1-dimethylamino-2-methylpentan-3-yl] phenol
Temazepam- (RS) -7-chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations that do not have any other substance in Annexes I to III, up to 20 mg Temazepam included-
Tetrazepam- 7-chloro-5-(cyclohex-1-enyl) -1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
except in preparations which contain up to 100 mg tetrazepam without any other substance in Annexes I to III
Tilidintrans-TilidinEthyl [(1RS, 2SR)-2-dimethyl-amino-1-phenylcyclohex-3-enecarboxylate]
-
except in fixed-release solid-release preparations, which without a further substance in Annexes I to III, up to 300 mg of Tilidin, calculated as base, and, based on this quantity, at least 7.5 of the 100 naloxone hydrochloride included-
Triazolam-8-Chloro-6-(2-chlorophenyl) -1-methyl-4H-[1,2, 4] triazolo [4,3-a] [1, 4] benzodiazepine
-
except in preparations that do not have any other substance in Annexes I to III Split form up to 025 mg Triazolam-
Zolpidem- N, N-Dimethyl-2-[ 6-methyl-2-(p-toly) imidazo [1,2-a] pyridin-3-yl] acetamide
-
except in preparations for oral use, which contain up to 8.5 mg of zolpidem, calculated as base, without any other substance in Annexes I to III, up to 8.5 mg of zolpidem -
-
the salts and Molecular compounds of the substances listed in this Annex, if they are used in medical, dental or veterinary medicine, in accordance with the findings of medical science;
-
the preparations of the substances listed in this Appendix if they do
a)
not being used on or in the human or animal body, only diagnostic for analytical purposes and their content of one or more narcotic agents, in the case of lyophilisates and corresponding mixtures of substances to be used in the ready-to-use solution, in each case not exceeding 0.01 of the hundred, or the substances in the Preparations isotopenmodified or
b)
are particularly excluded. However, the rules on the import, export and transit of drugs, other than those with codeine or dihydrocodeine, are subject to the rules governing the use of drugs. However, preparations which have been excluded under point (b) of the Barbital position may be ingested or carried out without authorisation in accordance with Article 11 of the Narcotics Act, if, in the circumstances, there is no reason to fear abuse of the product.